<SEC-DOCUMENT>0001213900-25-119651.txt : 20251209
<SEC-HEADER>0001213900-25-119651.hdr.sgml : 20251209
<ACCEPTANCE-DATETIME>20251209160103
ACCESSION NUMBER:		0001213900-25-119651
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20251208
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20251209
DATE AS OF CHANGE:		20251209

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Pluri Inc.
		CENTRAL INDEX KEY:			0001158780
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				980351734
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31392
		FILM NUMBER:		251558982

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 5
		CITY:			HAIFA
		PROVINCE COUNTRY:   	L3
		BUSINESS PHONE:		972-74-710-7171

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		MATAM ADVANCED TECHNOLOGY PARK
		STREET 2:		BUILDING NO. 5
		CITY:			HAIFA
		PROVINCE COUNTRY:   	L3

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLURISTEM THERAPEUTICS INC
		DATE OF NAME CHANGE:	20071228

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLURISTEM LIFE SYSTEMS INC
		DATE OF NAME CHANGE:	20030701

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AI SOFTWARE INC
		DATE OF NAME CHANGE:	20010906
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0269001-8k_pluri.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:PLUR="http://pluri-biotech.com/20251208">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_PLUR_pluri%2Dbiotech.com_20251208 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20251208_20251208 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001158780 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000004" name="dei:EntityCentralIndexKey">0001158780</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="plur-20251208.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-12-08">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001158780</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-12-08</xbrli:startDate>
        <xbrli:endDate>2025-12-08</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, DC 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_902_edei--DocumentType_c20251208__20251208_zuwT1m4s2Tzb"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT PURSUANT<br/>
TO SECTION 13 OR 15(d) OF THE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES EXCHANGE ACT OF 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
<b>December 9, 2025 (<span id="xdx_905_edei--DocumentPeriodEndDate_c20251208__20251208_zShc8qTysBwl"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">December 8, 2025</ix:nonNumeric></span>)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_905_edei--EntityRegistrantName_c20251208__20251208_zemXqoJj9bG8"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000011" name="dei:EntityRegistrantName">PLURI INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityIncorporationStateCountryCode_c20251208__20251208_zh3Fq77R3389"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt-sec:stateprovnameen" id="Fact000012" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_900_edei--EntityFileNumber_c20251208__20251208_z801DkcKdRXl"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000013" name="dei:EntityFileNumber">001-31392</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center; width: 32%"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityTaxIdentificationNumber_c20251208__20251208_zZMJueFcCFg6"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000014" name="dei:EntityTaxIdentificationNumber">98-0351734</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(State or Other Jurisdiction<br/>
of Incorporation)</span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Commission File Number)</span></td>
    <td style="vertical-align: bottom; text-align: center">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(IRS Employer<br/>
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: bottom; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20251208__20251208_zUtgVMBTtNbi"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000015" name="dei:EntityAddressAddressLine1">MATAM Advanced Technology Park</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; text-align: right; width: 2%">&#160;</td>
    <td style="vertical-align: top; text-align: center; width: 49%">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityAddressAddressLine2_c20251208__20251208_zjzlLSqrscE"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000016" name="dei:EntityAddressAddressLine2">Building No. 5</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: center">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityAddressCityOrTown_c20251208__20251208_zvM0KPAyN72k"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000017" name="dei:EntityAddressCityOrTown">Haifa</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressCountry_c20251208__20251208_zKbsDYSl2FM3"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt-sec:countrynameen" id="Fact000018" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressPostalZipCode_c20251208__20251208_znLkCAyiBEW1"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000019" name="dei:EntityAddressPostalZipCode">3508409</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Address of Principal Executive Offices)</span></td>
    <td style="vertical-align: bottom; text-align: right">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt">(Zip Code)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--CityAreaCode_c20251208__20251208_zK7RHgP36kR5"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000020" name="dei:CityAreaCode">011</ix:nonNumeric></span> <span id="xdx_900_edei--LocalPhoneNumber_c20251208__20251208_zZMkZeH6NdP7"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000021" name="dei:LocalPhoneNumber">972 74 710 7171</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed since
last report)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90C_edei--WrittenCommunications_c20251208__20251208_zW6I6ngd2K4l"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt:booleanfalse" id="Fact000022" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_904_edei--SolicitingMaterial_c20251208__20251208_zbMay1GXELid"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt:booleanfalse" id="Fact000023" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90D_edei--PreCommencementTenderOffer_c20251208__20251208_zFoFGHWL6oXf"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20251208__20251208_zQ8WRghE0p37"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt:booleanfalse" id="Fact000025" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td><span style="font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Title of each class</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Trading Symbol(s)</b></span></td>
    <td style="text-align: center; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_90B_edei--Security12bTitle_c20251208__20251208_zD5Ny28Tfmc8"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000026" name="dei:Security12bTitle">Common Shares, par value $0.00001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt"><span id="xdx_903_edei--TradingSymbol_c20251208__20251208_z26KAspdgQgc"><ix:nonNumeric contextRef="AsOf2025-12-08" id="Fact000027" name="dei:TradingSymbol">PLUR</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span style="font-size: 10pt">The <span id="xdx_907_edei--SecurityExchangeName_c20251208__20251208_zjI8jHm2Vf5h"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt-sec:exchnameen" id="Fact000028" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule
12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_904_edei--EntityEmergingGrowthCompany_c20251208__20251208_zM15SZd2hli5"><ix:nonNumeric contextRef="AsOf2025-12-08" format="ixt:booleanfalse" id="Fact000029" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 1.01 Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">On
December 8, 2025, Pluri Inc. (the &#8220;Company&#8221;) entered into a Securities Purchase Agreement (the &#8220;Securities Purchase
Agreement&#8221;) with Chutzpah Holdings LP (the &#8220;Purchaser&#8221;), a limited partnership beneficially owned by Mr. Alexandre Weinstein,
a non-U.S. investor and an existing shareholder and director of the Company (&#8220;Mr. Weinstein&#8221;), relating to a private placement
offering (the &#8220;Offering&#8221;) of: (i) 625,000 common shares, par value $0.00001 per share (the &#8220;Common Shares&#8221;) of
the Company, and (ii) warrants (the &#8220;Common Warrants&#8221;) to purchase up to 625,000 Common Shares. The combined purchase price
for each Common Share and Common Warrant is $4.00. The Common Warrants will be exercisable immediately at an exercise price of $4.25 per
share and will be exercisable until June 30, 2026. The Common Warrants contain customary anti-dilution provisions and are subject to a
35% beneficial ownership limitation. The Securities Purchase Agreement contains customary representations, warranties and indemnification
obligations of the parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
gross proceeds to the Company from the Offering are expected to be approximately $2.5 million. The Company intends to use the proceeds
from the Offering for working capital and general corporate purposes. The Offering is expected to close on or about December 15, 2025,
subject to the satisfaction of customary closing conditions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">The
securities issued with respect to the Offering are exempt from the registration requirements of the Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), pursuant to Section 4(a)(2) of the Securities Act and/or Rule 903 of Regulation S promulgated thereunder.
The securities have not been registered under the Securities Act and may not be sold in the United States absent registration or an exemption
from registration.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such state or jurisdiction.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The foregoing descriptions
of the Securities Purchase Agreement and the Common Warrants are qualified in their entirety by reference to the full text of the Securities
Purchase Agreement and the form of Common Warrants, copies of which are filed as Exhibits 10.1 and 4.1, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 3.02 Unregistered Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The response to this item
is included in Item 1.01, Entry into a Material Definitive Agreement, and is incorporated herein in its entirety.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 4, 2025, the Company&#8217;s
board of directors (the &#8220;Board&#8221;) granted an aggregate of 10,248 restricted stock units (&#8220;RSUs&#8221;) to the Chief Executive
Officer and Chief Financial Officer and an aggregate of 2,885 RSUs to Board members in lieu of cash compensation under the Company&#8217;s
2019 Equity Compensation Plan, with all RSUs vesting in equal monthly installments over three months. These grants were made to support
the Company&#8217;s cost-management initiatives and to align leadership incentives with long-term performance objectives.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 8.01 Other Events.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effective
December 4, 2025, Mr. Weinstein was appointed by the Board as Chairman of the Board, and Mr. Zami Aberman was appointed by the Board as
Vice Chairman of the Board. In connection therewith, Mr. Aberman&#8217;s consultancy agreement with the Company will be terminated effective
January 4, 2026.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Item 9.01 Financial Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">(d)
Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ea026900101ex4-1_pluri.htm">Form of Warrant</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt"><a href="ea026900101ex10-1_pluri.htm">Securities Purchase Agreement</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104 </span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document) <span style="text-decoration: underline"></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Safe Harbor Statement</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Current Report on Form
8-K contains express or implied forward-looking statements within the Private Securities Litigation Reform Act of 1995 and other U.S.
Federal securities laws. For example, the Company is using forward-looking statements when it discusses the expected closing of the Offering,
the receipt of the proceeds from the Offering and the intended use of the proceeds from the Offering. These forward-looking statements
and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors
and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following
factors, among others, could cause actual results to differ materially from those described in the forward-looking statements about the
Company: the conditions to the closing of the Offering may not be met; changes in technology and market requirements; the Company may
encounter delays or obstacles in launching and/or successfully completing its clinical trials, if necessary; the Company&#8217;s products
may not be approved by regulatory agencies; the Company&#8217;s technology may not be validated as it progresses further and its methods
may not be accepted by the scientific community; the Company may be unable to retain or attract key employees whose knowledge is essential
to the development of its products; unforeseen scientific difficulties may develop with the Company&#8217;s processes; the Company&#8217;s
products may wind up being more expensive than it anticipates; results in the laboratory may not translate to equally good results in
real clinical settings; the Company&#8217;s patents may not be sufficient; the Company&#8217;s products may harm recipients or consumers;
changes in legislation with an adverse impact; inability to timely develop and introduce new technologies, products and applications;
and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of the
Company to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, the Company
undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting
the Company, reference is made to the Company&#8217;s reports filed from time to time with the Securities and Exchange Commission.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-size: 10pt"><b>PLURI INC.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-size: 10pt">Date: December 9, 2025 </span></td>
    <td style="width: 5%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; width: 35%"><span style="font-size: 10pt">/s/ Liat Zalts</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Name: </span></td>
    <td><span style="font-size: 10pt">Liat Zalts</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title:</span></td>
    <td><span style="font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjVsKwkAMRVfQPYT5llpHFOynRYtYRYqIv4ONMthOSmZ8LcldGlvEEMjrnhulBiqnpa2R4TgvC9hj09YmIJR4RkZ3QlFkq3UKUku8WB/YuNCNPzAjYVCYaTw2su+Ud+uxSmGkh8lsqCfSpFrDbqOi7z0jd7YVumBNDcZVsGNq2WIw/Ood9uZJjppX9+mA7C05sYuT/vwGnYw0bOluHsRXD0WRqWjQRaRyplsrqsUzoPuSsKixkXe+p/8ZfQDLi0pc -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea026900101ex4-1_pluri.htm
<DESCRIPTION>FORM OF WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0"><B>Exhibit 4.1</B></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES INTO
WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY
STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN SECURED BY SUCH SECURITIES. THE HOLDER OF THIS COMMON SHARES
PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT
EXCEPT AS HEREIN PROVIDED.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>COMMON SHARES PURCHASE WARRANT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PLURI INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; text-indent: 4in">Issue Date: ___________, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Warrant Shares: <U>625,000</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">THIS COMMON SHARES
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, <U>Chutzpah Holdings LP</U>, registered office
337 WINSTON ROAD OAKVILLE Ontario (CA-ON), L6L 4W6 CANADA, or its assigns (the &ldquo;<U>Holder</U>&rdquo;) is entitled, upon the terms
and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ___________, 2025 (the &ldquo;<U>Initial
Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on June 30, 2026, but not thereafter (the &ldquo;<U>Termination
Date</U>&rdquo;), to subscribe for and purchase from Pluri Inc., a Nevada corporation (the &ldquo;<U>Company</U>&rdquo;), up to 625,000
shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;) of Common Shares. The purchase price of one Common
Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><U>Section 1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement
(the &ldquo;<U>Agreement</U>&rdquo;), dated December 8, 2025, between the Company and the Holder. In addition to the terms defined elsewhere
in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Business Day</U>&rdquo;
means any day except any Friday, Saturday, any Sunday, any day which is a federal legal holiday in the United States, Israel or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Common Shares Equivalents</U>&rdquo;
means any securities of the Company or its subsidiaries which would entitle the holder thereof to acquire at any time Common Shares, including,
without limitation, any debt, preferred shares, right, option, warrant or other instrument that is at any time convertible into or exercisable
or exchangeable for, or otherwise entitles the holder thereof to receive, Common Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Exchange Act</U>&rdquo;
means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Securities Act</U>&rdquo;
means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Trading Day</U>&rdquo;
means a day on which the Common Shares are traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Trading Market</U>&rdquo;
means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the date in question: the
NYSE, the NYSE MKT, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market, the New York Stock Exchange
or the OTC Bulletin Board (or any successors to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&ldquo;<U>Transfer Agent</U>&rdquo;
means <FONT STYLE="background-color: white">Equiniti Trust Company, LLC</FONT>, the current transfer agent of the Company, with a mailing
address of <FONT STYLE="background-color: white">55 Challenger Road, Floor 2, Ridgefield Park, NJ 07660</FONT>, and any successor transfer
agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><U>Section 2</U>.  <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Exercise
of Warrants</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company (or such other office or agency of
the Company as it may designate by notice in writing to the registered Holder at the address of the Holder appearing on the books of the
Company) of a duly executed facsimile copy (or e-mail attachment) of the Notice of Exercise in the form annexed hereto. Within the earlier
of (i) three (3) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined in Section 2(d)(i)
herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the shares specified in
the applicable Notice of Exercise by wire transfer drawn on a United States or Israeli bank. No ink-original Notice of Exercise shall
be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise form be required.
Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company
until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case,
the Holder shall surrender this Warrant to the Company for cancellation within five (5) Trading Days of the date the final Notice of Exercise
is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the total number of Warrant Shares
available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal
to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing the number of Warrant
Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1) Business
Day of receipt of such notice. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the
provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available
for purchase hereunder at any given time may be less than the amount stated on the face hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Exercise
Price</U>. The exercise price per share of the Common Shares under this Warrant shall be $4.25 per Warrant Share, subject to adjustment
hereunder (the &ldquo;<U>Exercise Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by Holder,
and otherwise by physical delivery of a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its
designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder
in the Notice of Exercise by the date that is the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the
Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price is received within the earlier of (i) three (3) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. As used herein, &ldquo;Standard
Settlement Period&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading
Market with respect to the Common Shares as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise in addition to any other action that
the Holder may exercise pursuant to applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall only be issued in the name of the Holder (or, if Written Consent has been obtained pursuant to Section 4(a), in the name
of the approved assignee ); <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than
the name of the Holder, subject to receipt of Written Consent, this Warrant when surrendered for exercise shall be accompanied by the
Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum
sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for same-day
processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing
similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi. <U>Closing
of Books</U>. The Company will not close its shareholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof, unless otherwise required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and the Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with (i) the Holder&rsquo;s Affiliates, (ii) any other Persons
acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates, and (iii) any other Persons whose beneficial ownership
of Common Shares would or could be aggregated with the Holder&rsquo;s for the purposes of Section 13(d) (such Persons, &ldquo;Attribution
Parties&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing
sentence, the number of Common Shares beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of Warrant Shares issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the
number of Warrant Shares which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially
owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted
portion of any other securities of the Company (including, without limitation, any other Common Shares Equivalents) subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution
Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(d), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder
that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange Act and the
Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this Section 2(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder
together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion
of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination of whether this Warrant
is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which
portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation
to verify or confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance
with the Beneficial Ownership Limitation, except to the extent the Holder relies on the number of outstanding Common Shares that was provided
by the Company. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section
13(d) of the Exchange Act and the rules and regulations promulgated thereunder, and the Company shall have no obligation to verify or
confirm the accuracy of such determination and shall have no liability for exercises of the Warrant that are not in compliance with the
Beneficial Ownership Limitation. For purposes of this Section 2(d), in determining the number of outstanding Common Shares, a Holder may
rely on the number of outstanding Common Shares as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with
the Securities and Exchange Commission (the &ldquo;Commission&rdquo;), as the case may be, (B) a more recent public announcement by the
Company or (C) a more recent written notice by the Company or the Transfer Agent setting forth the number of Common Shares outstanding.
Upon the written or oral request of a Holder, the Company shall within one Trading Day confirm orally and in writing to the Holder the
number of Common Shares then outstanding. In any case, the number of outstanding Common Shares shall be determined after giving effect
to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties
since the date as of which such number of outstanding Common Shares was reported. The &ldquo;Beneficial Ownership Limitation&rdquo; shall
be 35% of the number of Common Shares outstanding immediately after giving effect to the issuance of the Warrant Shares issuable upon
exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions
of this Section 2(d), provided that the Beneficial Ownership Limitation in no event exceeds 35% of the number of Common Shares outstanding
immediately after giving effect to the issuance of Warrant Shares upon exercise of this Warrant held by the Holder and the provisions
of this Section 2(d) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st
day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise
than in strict conformity with the terms of this Section 2(d) to correct this paragraph (or any portion hereof) which may be defective
or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable
to properly give effect to such limitation. The limitations contained in this paragraph apply to a successor holder of this Warrant. If
the Warrant is unexercisable solely because of the Holder&rsquo;s Beneficial Ownership Limitation, no alternate consideration is owing
to the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.
 <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Share
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a share dividend or otherwise makes
a distribution or distributions on shares of its Common Shares or any other equity or equity equivalent securities payable in Common Shares
(which, for avoidance of doubt, shall not include Common Shares issued by the Company upon exercise of this Warrant), (ii) subdivides
outstanding Common Shares into a larger number of shares, (iii) combines (including by way of reverse share split) outstanding Common
Shares into a smaller number of shares, or (iv) issues by reclassification of Common Shares, any shares of capital stock of the Company,
then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the number of Common Shares (excluding
treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number Common Shares outstanding
immediately after such event, and the number of shares issuable upon exercise of this Warrant shall be proportionately adjusted such that
the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective
immediately after the record date for the determination of shareholders entitled to receive such dividend or distribution and shall become
effective immediately after the effective date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Shares Equivalents or rights to purchase share, warrants, securities or other property pro rata to the record holders of any
class of Common Shares (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms applicable
to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of Common
Shares acquirable upon complete exercise of this Warrant, subject to the Beneficial Ownership Limitation, immediately before the date
on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which
the record holders of Common Shares are to be determined for the grant, issue or sale of such Purchase Rights (provided, however, to the
extent that the Holder&rsquo;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such
Common Shares as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for
the Holder until the such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of Common Shares, by way of return of capital or otherwise (including, without
limitation, any distribution of cash, shares or other securities, property or options by way of a dividend, spin off, reclassification,
corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;), at any time after
the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number Common Shares acquirable upon complete exercise of this
Warrant (without regard to any limitations on exercise hereof, but subject to the Beneficial Ownership Limitation) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of
Common Shares are to be determined for the participation in such Distribution. To the extent that this Warrant has not been partially
or completely exercised at the time of such Distribution, such portion of the Distribution shall be held in abeyance for the benefit of
the Holder until the Holder has exercised this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company, directly or indirectly, effects any
sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series
of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another
Person) is completed pursuant to which holders of Common Shares are permitted to sell, tender or exchange their shares for other securities,
cash or property and has been accepted by the holders of more than 50% of the outstanding Common Shares, (iv) the Company, directly or
indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Shares
or any compulsory share exchange pursuant to which the Common Shares is effectively converted into or exchanged for other securities,
cash or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase
agreement or other business combination (including, without limitation, a reorganization, recapitalization, spin-off or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding Common Shares (not
including any Common Shares held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons
making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;),
then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without
regard to any limitation in Section 2(d) on the exercise of this Warrant), the number of Common Shares of the successor or acquiring corporation
or of the Company, if it is the surviving corporation, and any additional consideration (the &ldquo;<U>Alternate Consideration</U>&rdquo;)
receivable as a result of such Fundamental Transaction by a holder of the number of Common Shares for which this Warrant is exercisable
immediately prior to such Fundamental Transaction (without regard to any limitation in Section 2(d) on the exercise of this Warrant).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one Common Share in such Fundamental Transaction,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Shares are given any choice as to the securities, cash
or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration
it receives upon any exercise of this Warrant following such Fundamental Transaction. The Company shall cause any successor entity in
a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;) to assume in writing all
of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section
3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable
delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant
a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which
is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the
Common Shares acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant)
prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital
stock (but taking into account the relative value of the Common Shares pursuant to such Fundamental Transaction and the value of such
shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of protecting the economic
value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in
form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and
be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant and the other Transaction
Documents referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power
of the Company and shall assume all of the obligations of the Company under this Warrant and the other Transaction Documents with the
same effect as if such Successor Entity had been named as the Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of Common Shares deemed to be issued and outstanding as of a given date shall be the sum of the number of
Common Shares (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><U>i. Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, unless the Company otherwise
publishes any such adjustment via a public announcement, the Company shall promptly deliver to the Holder by facsimile or email a notice
setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth
a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"><U>ii. Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Shares, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of Common Shares, (C) the Company shall
authorize the granting to all holders of Common Shares rights or warrants to subscribe for or purchase any shares of capital stock of
any class or of any rights, (D) the approval of any shareholders of the Company shall be required in connection with any reclassification
of Common Shares, any consolidation or merger to which the Company is a party, any sale or transfer of all or substantially all of the
assets of the Company, or any compulsory share exchange whereby the Common Shares are converted into other securities, cash or property,
or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company,
then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile number or email
address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable record or effective
date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such dividend, distribution,
redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of Common Shares of record to be entitled
to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on which such reclassification, consolidation,
merger, sale, transfer or share exchange is expected to become effective or close, and the date as of which it is expected that holders
of Common Shares of record shall be entitled to exchange their Common Shares for securities, cash or other property deliverable upon such
reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect
therein or in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. To the
extent that any notice provided in this Warrant constitutes, or contains, material, non-public information regarding the Company or any
of its subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form 8-K. The
Holder shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of
the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.
 <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>Transferability</U>.
The Holder of this Warrant agrees by his, her or its acceptance hereof, that such Holder will not sell, transfer, assign, pledge or hypothecate
this Warrant, in whole or in part, whether voluntarily, involuntarily, by operation of law or otherwise, without the prior written consent
of the Company (the &ldquo;Written Consent&rdquo;), which the Company may grant or withhold in its sole discretion. Any attempted transfer,
assigning, pledging or hypothecating in violation of this Section 4(a) shall be null and void ab initio and shall confer no rights on
any purported assignee. Upon the Company&rsquo;s Written Consent, transfers to others, in whole or in part, may be made subject to compliance
with or exemptions from applicable securities laws. In order to make any permitted assignment, the Holder must deliver to the Company
the assignment form attached hereto duly executed and completed, together with the Purchase Warrant and payment of all transfer taxes,
if any, payable in connection therewith. The Company shall within ten (10) Business Days transfer this Warrant on the books of the Company
and shall execute and deliver a new Warrant or Warrants of like tenor to the appropriate assignee(s) expressly evidencing the right to
purchase the aggregate number of Shares purchasable hereunder or such portion of such number as shall be contemplated by any such assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with
this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, this Warrant shall
not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable state securities
or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information requirements
pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that (i) the Holder of this Warrant shall provide
to the Company an opinion of counsel selected by the Holder and reasonably acceptable to the Company, to the effect that such transfer
does not require registration of this Warrant under the Securities Act, and (ii) the transferee will agree to the imprinting of the legend
on this Warrant (in addition to any legend required by applicable state securities or &ldquo;blue sky&rdquo; laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.
 <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a) <U>No
Rights as Shareholder Until Exercise</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as
a shareholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth in Section 3.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any share certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or share certificate, if mutilated, the Company will make
and deliver a new Warrant or share certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or share certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c) <U>Fridays,
Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then, such action may be taken or such right may be exercised on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d) <U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">The Company covenants that it has reserved and will continue to reserve and keep available so long as this Warrant
remains outstanding, free of preemptive rights, from its authorized and unissued Common Shares a sufficient number of shares to
provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing
the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable
action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable
law or regulation, or of any requirements of the Trading Market upon which the Common Shares may be listed (including the Tel Aviv
Stock Exchange). The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights
represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant
Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and
charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e) <U>Governing
Law and Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant will be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principle
of conflicts of law thereof. The Holder and the Company agree that all legal proceedings concerning the interpretations, enforcement and
defense of this Warrant (whether brought against the Company, the Holder or its respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
The Company and the Holder hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City
of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith, and hereby irrevocably waives,
and agrees not to assert in any action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court,
that such action or proceeding is improper or is an inconvenient venue for such proceeding. If any party shall commence an action or proceeding
to enforce any provisions of this Warrant, then the prevailing party in such action or proceeding shall be reimbursed by the non-prevailing
party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the investigation, preparation and prosecution
of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered by the Company, will have
restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h) <U>Notices</U>.
All notices or other communications required or permitted to be given by the Company to the Holder or by the Holder to the Company shall
be delivered in writing in accordance with the notice details set forth below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">If to the Company:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Pluri Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Matam Advanced Technology Park, Building
No. 5</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Haifa, Israel 3508409</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Attention: Liat Zalts, Chief Financial
Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">E-mail: liat.zalts@Pluri-biotech.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">If to the Holder:&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Chutzpah Holdings LP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">337 WINSTON ROAD OAKVILLE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Ontario (CA-ON), L6L</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">4W6 CANADA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">Attention: Alejandro Weinstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">E-mail: alexandre@bechutzpah.ch</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of Common Shares or as a shareholder of the Company, whether such liability is asserted by the Company or by creditors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns (provided that a Written Consent was obtained in accordance with Section
4(a)) of the Company and the Holder. The provisions of this Warrant are intended to be for the benefit of the Holder, and in accordance
with Section 4(a), for the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of
Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I></I></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">IN WITNESS WHEREOF, the Company
has caused this Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3"><B>PLURI INC.</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD COLSPAN="3">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 6%">Name:&nbsp;</TD>
  <TD STYLE="width: 30%">Yaky Yanay</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>President &amp; Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 6%">Name:&nbsp;</TD>
  <TD STYLE="width: 30%"> Liat Zalts</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Financial Officer &amp; Treasurer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">TO: pluri
inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment
shall take the form of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">&#9744; in lawful money
of the United States</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please
issue said Warrant Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">_______________________</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Name of Investing Entity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">______________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Signature of Authorized Signatory of Investing
Entity</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Name of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">_____________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Title of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Date: ________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT B</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-weight: normal">ASSIGNMENT FORM</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To be completed only
in connection with a transfer approved by the Company in accordance with Section 4(a) of this Warrant. Do not use this form to purchase
shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, _________
does hereby sell, assign and transfer unto the right to purchase Common Shares of Pluri Inc. (the &ldquo;Company&rdquo;), a Nevada company,
evidenced by this Warrant and does hereby authorize the Company to transfer such right on the books of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; width: 47%; text-align: justify; font-size: 10pt">Name of Assignee (must be identical to the transferee approved in writing by the Company):</TD>
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; width: 53%; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; font-size: 10pt">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: justify; font-size: 10pt">Address of Assignee:</TD>
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">Phone Number of Assignee:</TD>
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid">Email Address of Assignee:</TD>
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding: 3pt; border-right: Black 1pt solid; border-left: Black 1pt solid">Tax Identification No. or equivalent, if applicable</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 3pt; border-right: Black 1pt solid; text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: Black 1pt solid; padding: 3pt; border-right: Black 1pt solid; border-left: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; padding: 3pt; border-right: Black 1pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding: 3pt; border: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="padding: 3pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: justify; font-size: 10pt">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned acknowledges that this transfer
has been expressly approved by the Company pursuant to Section 4(a) of the Warrant, and that any transfer made without such prior written
consent is null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: _____________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">__________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Signature of Holder)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">_____________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Name of Holder - please print)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea026900101ex10-1_pluri.htm
<DESCRIPTION>SECURITIES PURCHASE AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right">Exhibit 10.1</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES PURCHASE AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This Securities
Purchase Agreement (this &ldquo;<U>Agreement</U>&rdquo;) is dated as of <U>December 8, 2025</U>, between Pluri Inc., a Nevada corporation
(the &ldquo;<U>Company</U>&rdquo;), and the purchaser identified on the signature pages hereto (including its successors and assigns,
the &ldquo;<U>Purchaser</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.45pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">WHEREAS, subject
to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the
&ldquo;<U>Securities Act</U>&rdquo;) and Rule 506(b) of Regulation D and Rule 903 of Regulation S promulgated thereunder, the Company
desires to issue and sell to the Purchaser, and the Purchaser desires to purchase from the Company, (i) Common Shares, and (ii) Common
Warrants to purchase Common Shares equal to 100% of the sum of the Common Shares purchased by the Purchaser hereunder, as each such term
is defined below and more fully described in this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">NOW, THEREFORE,
IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the receipt and adequacy
of which are hereby acknowledged, the Company and the Purchaser agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE I.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms
have the meanings set forth in this Section 1.1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Friday, Saturday Sunday, any day which is a federal legal holiday in the United States, a legal
holiday in the State of Israel, or any day on which banking institutions in the State of New York or the State of Israel are authorized
or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing</U>&rdquo;
means the closing of the purchase and sale of the Shares pursuant to Section 2.1.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Closing
Date</U>&rdquo; means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable parties
thereto, and all conditions precedent to (i) the Purchaser&rsquo;s obligations to pay the Subscription Amount and (ii) the Company&rsquo;s
obligations to deliver the Shares, in each case, have been satisfied or waived.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo; means the United States Securities
and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Shares</U>&rdquo; means the common shares of the Company, par value $0.00001 per share, and any other class of securities into which
such securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Warrant</U>&rdquo; means the Common Shares purchase warrant delivered to the Purchaser at the Closing in accordance with Section 2.2(a)
hereof, in substantially the form of <U>Exhibit A</U> attached hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Disclosure
Time</U>&rdquo; means, (i) if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and
before midnight (New York City time) on any Trading Day, 9:01 a.m. (New York City time) on the Trading Day immediately following the date
hereof, and (ii) if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day,
no later than 9:01 a.m. (New York City time) on the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Holder</U>&rdquo; shall have the meaning ascribed
to such term in Section 4.8(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Liens</U>&rdquo;
means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right or other restriction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Material
Adverse Effect</U>&rdquo; means (i) a material adverse effect on the legality, validity or enforceability of any Transaction Document,
(ii) a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the
Company and its subsidiaries, taken as a whole, or (iii) a material adverse effect on the Company&rsquo;s ability to perform in any material
respect on a timely basis its obligations under any Transaction Document.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Per
Share Purchase Price</U>&rdquo; means $4.00, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations
and other similar transactions of shares of Common Stock that occur between the date hereof and the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Proceeding</U>&rdquo;
means an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding,
such as a deposition) pending or, to the Company&rsquo;s knowledge, threatened in writing against or affecting the Company, any Subsidiary
or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority
(federal, state, county, local or foreign).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>SEC Reports</U>&rdquo;
shall have the meaning ascribed to such term in Section 3.1(e). &ldquo;<U>Securities</U>&rdquo; means the Shares, the Warrants and the
Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Shares</U>&rdquo;
means the Common Shares issued or issuable to the Purchaser pursuant to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Short
Sales</U>&rdquo; means all &ldquo;short sales&rdquo; as defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be
deemed to include locating and/or borrowing Common Shares).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subscription
Amount</U>&rdquo; means, the aggregate amount of $2.5 million to be paid by the Purchaser for Shares and Warrants purchased hereunder
as specified below such Purchaser&rsquo;s name on the signature page of this Agreement and next to the heading &ldquo;Subscription Amount,&rdquo;
in United States dollars and in immediately available funds.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Shares are listed or quoted for trading on the date
in question: the Nasdaq Capital Market and the Tel Aviv Stock Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transaction
Documents</U>&rdquo; means this Agreement, the Warrants and all exhibits and schedules thereto and hereto and any other documents or agreements
executed in connection with the transactions contemplated hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Equiniti Trust Company, LLC, the current transfer agent of the Company, with a mailing address of 55 Challenger
Road, Floor 2, Ridgefield Park, NJ 07660, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo; means the Common Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrant
Shares</U>&rdquo; means the shares of Common Shares issuable upon exercise of the Warrants.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE II.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">PURCHASE AND SALE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">2.1 <U>Closing</U>.
On the Closing Date, upon the terms and subject to the conditions set forth herein, substantially concurrent with the execution and delivery
of this Agreement by the parties hereto, the Company agrees to sell, and the Purchaser agrees to purchase (i) the number of Common Shares
set forth under the heading &ldquo;Number of Shares&rdquo; on the Purchaser&rsquo;s signature page hereto, at the Per Share Purchase Price,
and (ii) Common Warrants to purchase up to the amount of Common Shares set forth under the heading &ldquo;Common Warrants&rdquo; on the
Purchaser&rsquo;s signature page hereto, exercisable for Common Shares as calculated pursuant to Section 2.2(a). Prior to Closing, the
Purchaser shall deliver to the Company, via wire transfer of immediately available funds in cash equal to its Subscription Amount, and
as of the Closing (i) the Company shall deliver to the Purchaser the Shares and the Warrants, and (ii) the Company and the Purchaser shall
deliver the other items set forth in Section 2.2 deliverable at the Closing. Upon satisfaction of the covenants and conditions set forth
in Sections 2.2 and 2.3, the Closing shall occur at the offices of legal counsel to the Company or such other location as the parties
shall mutually agree (and such Closing may be undertaken remotely by electronic exchange of documentation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> 2.2 <U>Deliveries</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(a) On
or prior to the Closing Date, the Company shall deliver or cause to be delivered to the Purchaser the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in"> (i) this Agreement duly executed by the Company;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(ii) on
the Closing Date, the Company shall cause the Transfer Agent to issue to the Purchaser in global form through a book-entry account maintained
by the Transfer Agent, the number of Common Shares set forth on such Purchaser&rsquo;s signature page hereto, registered in the name of
such Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in"><FONT STYLE="font-size: 10pt">(iii) on
the Closing Date, an originally singed Common Warrant registered in the name of the Purchaser to purchase up to the number of Common Shares
equal to 100% of Shares, with an exercise price equal to </FONT>$4.25 <FONT STYLE="font-size: 10pt">per share, subject to adjustment therein</FONT>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(iv) on
the Closing Date, the Purchaser shall have received a certificate signed by each of the Chief Executive Officer and Chief Financial Officer
of the Company certifying to the fulfillment of the conditions set forth in Section 2.3(b); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(v) on
the Closing Date, the Purchaser shall have received an opinion of Sullivan &amp; Worcester LLP, counsel for the Company, dated as of the
Closing Date in a form reasonably acceptable to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(b) On
or prior to the Closing Date, the Purchaser shall deliver or cause to be delivered to the Company the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in"> (i) this Agreement duly executed by the Purchaser;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(ii) if
the Purchaser is an Accredited Investor (as defined herein), an executed copy of the Accredited Investor Questionnaire set forth on <U>Exhibit
B-1</U>;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(iii) if
the Purchaser is a Non-U.S. Person (as defined herein), an executed copy of the Regulation S Questionnaire set forth on <U>Exhibit B-2</U>;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(iv) the
Purchaser&rsquo;s Subscription Amount, which shall be made available for &ldquo;Delivery Versus Payment&rdquo; settlement with the Company
or its designees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> 2.3 <U>Closing Conditions</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(a) The
obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Purchaser contained herein (unless as
of a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(ii) all
obligations, covenants and agreements of the Purchaser required to be performed at or prior to the Closing Date shall have been performed;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(iii) the
delivery by the Purchaser of the items set forth in Section 2.2(b) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(b) The
respective obligations of the Purchaser hereunder in connection with the Closing are subject to the following conditions being met:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(i) the
accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect,
in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless as of
a specific date therein in which case they shall be accurate as of such date);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(ii) all
obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall have been performed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(iii) the
delivery by the Company of the items set forth in Section 2.2(a) of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(iv) there
shall have been no Material Adverse Effect with respect to the Company since the date hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(v) the
Company shall have filed additional listing applications and/or notices of each of the Nasdaq Capital Market and the Tel Aviv Stock Exchange
(the &ldquo;<U>TASE</U>&rdquo;) for the listing of the Common Shares and the Warrant Shares issued and issuable to the Purchaser pursuant
to the Transaction Documents; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1.5in">(vi) the
Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the
purchase and sale of the Securities and the consummation of the other transactions contemplated by this Agreement, including the waiver
of any applicable registration rights that could affect the rights of the Purchaser hereunder, all of which shall be in full force and
effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE III.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">3.1 <U>Representations
and Warranties of the Company</U>. The Company hereby makes the following representations and warranties to the Purchaser:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(a) <U>Organization
and Standing</U>. Each of the Company and each of its subsidiaries has been (i) duly organized and is validly existing and in good standing
(where such concept exists) under the laws of its jurisdiction of organization, with power and authority (corporate and other) to own
its properties and conduct its business as currently conducted, and (ii) duly qualified as a foreign corporation for the transaction of
business and is in good standing (where such concept exists) under the laws of each other jurisdiction in which it owns or leases properties
or conducts any business so as to require such qualification, except where the failure to be so qualified or in good standing would not,
individually or in the aggregate, have a Material Adverse Effect. The certificate of incorporation, articles of association and by-laws
(and other applicable organizational documents) of the Company and each of its subsidiaries comply with the requirements of applicable
law in its jurisdiction of incorporation and are in full force and effect and except as set forth in the SEC Reports, the Company owns,
directly or through subsidiaries, all of the issued outstanding equity securities of each of its subsidiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(b) <U>Corporate
Power; Authorization</U>. This Agreement and each of the other Transaction Documents has been duly authorized, executed and delivered
by the Company; the Company has all requisite corporate power and authority to execute, deliver and perform its obligations under this
Agreement and each of the other Transaction Documents. This Agreement and each of the other Transaction Documents is the valid and binding
obligation of the Company enforceable against the Company in accordance with its terms, except (i) as limited by general equitable principles
and applicable bankruptcy, insolvency, reorganization, moratorium and other </FONT>laws of general application affecting enforcement of
creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief or
other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(c) <U>Issuance
and Delivery of the Securities</U>. The Shares have been duly authorized and, when issued and paid for in compliance with the provisions
of this Agreement, will be validly issued, fully paid and non-assessable, and issued in compliance with all applicable law. The Warrants
have been duly authorized by the Company and when executed and delivered by the Company will be valid and binding agreements of the Company,
enforceable against the Company in accordance with their terms. The issuance and delivery of the Shares or Warrants is not subject to
preemptive, co-sale, right of first refusal or any other similar rights of the shareholders of the Company or any other Person or any
liens or encumbrances. The Warrant Shares have been duly authorized and reserved for issuance and, when issued and delivered upon valid
exercise of the Warrants in accordance therewith, will be validly issued, fully paid and nonassessable and issued in compliance with all
applicable law, and not subject to preemptive, co-sale, right of first refusal or any other similar rights of the shareholders of the
Company or any other Person or any liens or encumbrances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(d) <U>Registration
Exemption</U>. The offer and issuance by the Company of the Securities is exempt from registration under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(e) <U>SEC
Reports</U>. The Company is subject to the reporting requirements of the Exchange Act, and has filed or will file in a timely manner all
reports, schedules, forms, statements and other documents that the Company was or is required to file with the Commission under either
the Securities Act or the Exchange Act, since becoming subject to the requirements of the Exchange Act (the foregoing documents (together
with any documents filed by the Company under the Securities Act or Exchange Act, whether or not required), and in each case including
all exhibits and schedules thereto and documents incorporated by reference therein and including all registration statements and prospectuses
filed with the Commission, but excluding any information for which the Company has received confidential treatment from the Commission,
being collectively referred to herein as the &ldquo;<U>SEC Reports</U>&rdquo;), all of which are available on the Commission&rsquo;s EDGAR
system. As of their respective filing or furnishing dates (or, if amended prior to the date of this Agreement, when amended), all SEC
Reports (including any audited or unaudited financial statements and any notes thereto or schedules included therein) complied in all
material respects with the requirements of the Securities Act or the Exchange Act, as the case may be, and the rules and regulations of
the Commission promulgated thereunder. None of the SEC Reports as of their respective filing or furnishing dates contained any untrue
statement of material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made
therein, in light of the circumstances under which they were made, not misleading. There are no material outstanding or unresolved comments
in comment letters from the staff of the Division of Corporation Finance of the Commission with respect to any SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">(f) <U>Tel
Aviv Stock Exchange Reporting</U>. All statements, reports, schedules, forms and other documents (and all exhibits, supplements and amendments)
required to have been published and/or filed by the Company pursuant to applicable law with the Israel Securities </FONT>Authority and
the TASE have been so published and/or filed and/or furnished, as applicable, on a timely basis (the &ldquo;<U>TASE Reporting Document</U>&rdquo;).
As of the time it was published and/or filed and/or furnished, as applicable, other than as corrected in a subsequent TASE Reporting Document:
(i) each of the TASE Reporting Documents complied in all material respects with applicable laws as in effect on the date such TASE Reporting
Document was filed; and (ii) none of the TASE Reporting Documents contained any untrue statement of a material fact or omitted to state
a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(g) <U>No
General Solicitation</U>. Neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf, has engaged in
any form of general solicitation or general advertising (within the meaning of Regulation D promulgated under the Securities Act) in connection
with the offer or sale of the Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(h) <U>No
&ldquo;Bad Actor&rdquo; Disqualification</U>. No &ldquo;bad actor&rdquo; disqualifying event described in Rule 506(d)(1)(i)-(viii) of
the Securities Act (a &ldquo;<U>Disqualification Event</U>&rdquo;) is applicable to the Company or, to the Company&rsquo;s knowledge,
any Company Covered Person (as defined below), except for a Disqualification Event to which Rule 506(d)(2)(ii-iv) or (d)(3) is applicable.
&ldquo;<U>Company Covered Person</U>&rdquo; means, with respect to the Company as an &ldquo;issuer&rdquo; for purposes of Rule 506 promulgated
under the Securities Act, any person listed in the first paragraph of Rule 506(d)(1).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(i) <U>No
Material Adverse Effect</U>. Except as otherwise disclosed in the SEC Reports, subsequent to the respective dates as of which information
is given in the SEC Reports: (i) there has been no change which has had or would reasonably be expected to result in a Material Adverse
Effect; (ii) the Company and its subsidiaries, considered as one entity, have not incurred any material liability or obligation, indirect,
direct or contingent, not in the ordinary course of business nor entered into any material transaction or agreement not in the ordinary
course of business; (iii) there has been no dividend or distribution of any kind declared, paid or made by the Company; (iv) no executive
officer or director of the Company has resigned from any position with the Company; and (v) there has not been any Material Adverse Effect
in the Company&rsquo;s long-term or short-term debt.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(j) <U>Independent
Accountants</U>. To the knowledge of the Company, Kesselman &amp; Kesselman, whose report is filed with the Commission and included or
incorporated by reference in the SEC Reports, is an independent registered public accounting firm as required by the Securities Act and
the Public Company Accounting Oversight Board and a member firm of PricewaterhouseCoopers International Limited. Kesselman &amp; Kesselman
has not, during the periods covered by the financial statements included or incorporated by reference in the SEC Reports, provided to
the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(k) <U>Financial
Statements</U>. The financial statements filed with the Commission and included in the SEC Reports, together with the related notes
and schedules, present fairly, in all material respects, the consolidated financial position of the Company and its subsidiaries as
of and at the dates indicated and the results of their operations and cash flows for the periods therein specified. Such financial
statements and supporting schedules have been prepared in conformity with U.S. generally accepted accounting principles
(&ldquo;<U>GAAP</U>&rdquo;) applied on a consistent basis throughout the periods involved, except as may be expressly stated in the
related notes thereto, provided, that, unaudited interim financial statements are subject to year-end audit adjustments that are not
expected to be material in the aggregate and do not contain all footnotes required by GAAP. No other financial statements or
supporting schedules are required to be included in or incorporated by reference in the SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> (l) <U>[Reserved].</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(m) <U>Statistical
and Marketing-Related Data</U>. The statistical and market-related data included or incorporated by reference in SEC Reports are based
on or derived from sources that the Company reasonably and in good faith believes are reliable and accurate or represent the Company&rsquo;s
good faith estimates that are made on the basis of data derived from such sources.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(n) <U>XBRL</U>.
The interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Reports fairly presents
the information called for in all material respects and has been prepared in accordance with the Commission&rsquo;s rules and guidelines
applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(o) <U>Capitalization</U>.
The authorized share capital of the Company is as set forth on Schedule 3.1(o). As set forth in the SEC Reports as of the date set
forth therein, all of the issued and outstanding Common Shares of the Company have been duly and validly authorized and issued and
are fully paid and non-assessable, have been issued in compliance with all applicable law, and conform to the description of the
Common Shares contained in the SEC Reports; and all of the issued shares of each subsidiary of the Company have been duly and
validly authorized and issued, are fully paid and non-assessable are owned directly or indirectly by the Company, free and clear of
all liens, encumbrances, equities or claims, except for such liens or encumbrances described in the SEC Reports, there are no
options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company any shares of the
share capital of the Company; the Common Shares to be issued and sold by the Company to the Purchaser hereunder have been duly and
validly authorized and, when issued and delivered against payment therefor as provided herein, will be duly and validly issued and
fully paid and non-assessable and will conform to the description of the ordinary shares contained in the SEC Reports; the issuance
of the Shares is not subject to any preemptive or similar rights; the description of the Company&rsquo;s share option, RSUs, share
bonus and other share plans or arrangements (the &ldquo;<U>Company Share Plans</U>&rdquo;), and the options and other equity
incentive awards or other rights granted thereunder (collectively, the &ldquo;<U>Options</U>&rdquo;), set forth in the SEC Reports
accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights;
each grant of an Option (A) was duly authorized no later than the date on which the grant of such Option was by its terms to be
effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly
constituted and authorized committee thereof) and any required shareholder approval by the necessary number of votes or written
consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (B) that was
intended to qualify for either the &ldquo;capital gains track&rdquo; or the &ldquo;employment income track&rdquo; of Section 102 of
the Israeli Income Tax Ordinance (New Version), 5721-1961, and the rules and regulations promulgated thereunder, so qualifies as was
indicated with respect to each such Option at the date that such Option was granted, and (C) was made in accordance with the terms
of the applicable Company Share Plan and applicable laws and regulatory rules or requirements, including all applicable federal and
Israeli securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(p) <U>Non-Contravention
of Existing Instruments; No Further Authorizations or Approvals Required</U>. The Company&rsquo;s execution, delivery and performance
of this Agreement and consummation of the transactions contemplated hereby or by the Transaction Documents (including the issuance and
sale of the Securities and the use of the proceeds from the sale of the Securities will not (A) result in a material breach or violation
of any of the terms and provisions of, or constitute a default under, any law, order, rule or regulation to which the Company or any subsidiary
is subject (including, without limitation, those promulgated by the Food and Drug Administration of the U.S. Department of Health and
Human Services (the &ldquo;<U>FDA</U>&rdquo;) or by any foreign, federal, state or local regulatory authority performing functions similar
to those performed by the FDA), or by which any property or asset of the Company or any subsidiary is bound or affected, (B) conflict
with, result in any violation or breach of, or constitute a default (or an event that with notice or lapse of time or both would become
a default) under, or give to others any right of termination, amendment, acceleration or cancellation (with or without notice, lapse of
time or both) (a &ldquo;<U>Default Acceleration Event</U>&rdquo;) of, any agreement, lease, credit facility, debt, note, bond, mortgage,
indenture or other instrument (&ldquo;<U>Contract</U>&rdquo;) or obligation or other understanding to which the Company or any subsidiary
is a party or by which any property or asset of the Company or any subsidiary is bound or affected or any instrument of approval granted
to it by the Israel Innovation Authority of the Israeli Ministry of Economy and Industry or any instrument of approval granted to any
of them by the Authority for Investment and Development of Industry and the Economy of the Israeli Ministry of Economy and Industry, except
to the extent that such conflict, default, or Default Acceleration Event is not reasonably likely to result in a Material Adverse Effect,
or (C) result in a breach or violation of any of the terms and provisions of, or constitute a default under, the Company&rsquo;s articles
of incorporation (as the same may be amended or restated from time to time) or bylaws (as the same may be amended or restated from time
to time). Except as set forth in the SEC Reports, neither the Company nor any of its subsidiaries is in violation, breach or default under
its articles of incorporation (as the same may be amended or restated from time to time), bylaws (as the same may be amended or restated
from time to time) or other equivalent organizational or governing documents. The Company nor, to its knowledge, any other party is in
violation, breach or default of any Contract that has resulted in or could reasonably be expected to result in a Material Adverse Effect.
Each approval, consent, order, authorization, designation, declaration or filing by or with any regulatory, administrative or other governmental
body necessary in connection with the execution and delivery by the Company of this Agreement and the performance of the Company of the
transactions herein contemplated has been obtained or made and is in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(q) <U>No Material
Actions or Proceedings</U>. There is no action, suit, proceeding, inquiry, arbitration, investigation, litigation or governmental
proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to the Company&rsquo;s
knowledge, any executive officer or director of the Company including any proceeding before the FDA or comparable federal, state,
local or foreign governmental bodies (it being understood that the interaction between the Company and the FDA and such comparable
governmental bodies relating to the clinical development and product approval process shall not be deemed proceedings for purposes
of this representation), which is required to be disclosed and has not been disclosed in the SEC Reports, except as would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(r) <U>Labor
Disputes</U>. Except as set forth in the SEC Reports, there is not pending or, to the knowledge of the Company, threatened, any action,
suit or proceeding to which the Company or any of its subsidiaries is a party or of which any property or assets of the Company or any
of its subsidiaries is the subject before or by any court or governmental agency, authority or body, or any arbitrator or mediator, except
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(s) <U>Compliance
with Certain Applicable Laws</U>. The Company: (A) is and at all times has been in compliance with all statutes, rules, or regulations
applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion,
sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (&ldquo;<U>Applicable
Laws</U>&rdquo;), except as could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; (B)
has not received any warning letter, untitled letter or other correspondence or notice from any governmental authority alleging or asserting
noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or
amendments thereto required by any such Applicable Laws (&ldquo;<U>Authorizations</U>&rdquo;) the receipt of which could, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect; (C) possesses all material Authorizations and such Authorizations
are valid and in full force and effect and are not in material violation of any term of any such Authorizations; (D) has not received
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any governmental
authority or third party alleging that any product operation or activity is in violation of any Applicable Laws or Authorizations and
has no knowledge that any such governmental authority or third party is considering any such claim, litigation, arbitration, action, suit,
investigation or proceeding, the receipt of which could, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; (E) has not received notice that any governmental authority has taken, is taking or intends to take action to limit, suspend,
modify or revoke any Authorizations and has no knowledge that any such governmental authority is considering such action; and (F) has
filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments were complete and correct on the date filed (or were corrected or supplemented
by a subsequent submission).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(t) <U>Tax Law
Compliance</U>. Other than as disclosed in the SEC Reports, except for matters that would not, individually or in the aggregate,
have or reasonably be expected to result in a Material Adverse Effect each of the Company and its subsidiaries has (a) filed all
material foreign, federal, state and local tax returns (as hereinafter defined) required to be filed with taxing authorities prior
to the date hereof or has duly obtained extensions of time for the filing thereof and (b) paid all taxes (as hereinafter defined)
shown as due and payable on such returns that were filed and has paid all taxes imposed on or assessed against the Company or such
respective subsidiary. The provisions for taxes payable, if any, shown on the financial statements included or incorporated by
reference in the SEC Reports are sufficient for all accrued and unpaid taxes, whether or not disputed, and for all periods to and
including the dates of such consolidated financial statements. Other than as disclosed in the SEC Reports, no material issues have
been raised (and are currently pending) by any taxing authority in connection with any of the returns or taxes asserted as due from
the Company or its subsidiaries, and no waivers of statutes of limitation with respect to the returns or collection of taxes have
been given by or requested from the Company or its subsidiaries. There are no tax liens against the assets, properties or business
of the Company or any of its subsidiaries. The term &ldquo;taxes&rdquo; mean all federal, state, local, foreign, and other net
income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license, lease, service, service use,
withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits, customs, duties or
other taxes, fees, assessments, or charges of any kind whatever, together with any interest and any penalties, additions to tax, or
additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements, and
other documents required to be filed in respect to taxes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(u) <U>Company
Not an &ldquo;Investment Company&rdquo;</U>. The Company is not, and will not be, either after receipt of payment for the Securities or
after the application of the proceeds therefrom to register as an &ldquo;investment company&rdquo; under the Investment Company Act of
1940, as amended (the &ldquo;Investment Company Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(v) <U>Insurance</U>.
The Company and each of its subsidiaries carries, or is entitled to the benefits of insurance in such amounts and covering such risks,
which the Company believes are adequate for the conduct of its business and the value of its properties and as is customary for companies
engaged in similar businesses in similar industries, and all such insurance is in full force and effect. Neither the Company nor any of
its subsidiaries has reason to believe that it will not be able (i) to renew its existing insurance coverage as and when such policies
expire or (ii) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now
conducted and at a cost that would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(w) <U>No
Price Stabilization or Manipulation</U>. The Company has not taken, directly or indirectly, any action designed to or that might cause
or result in stabilization or manipulation of the price of the Common Shares or of any &ldquo;reference security&rdquo; (as defined in
Rule 100 of Regulation M under the Exchange Act (&ldquo;Regulation M&rdquo;)) with respect to the Common Shares, whether to facilitate
the sale or resale of the Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation M.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(x) <U>Related
Party Transactions</U>. There are no business relationships or related party transactions involving the Company or any other person required
to be described in the SEC Reports that have not been described as required pursuant to the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(y) <U>Compliance
with Environmental Laws</U>. The Company and its subsidiaries are in compliance with all foreign, federal, state and local rules,
laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection
of health and safety or the environment which are applicable to their businesses (&ldquo;<U>Environmental Laws</U>&rdquo;), except
where the failure to comply has not had and would not reasonably be expected to result in, singularly or in the aggregate, a
Material Adverse Effect. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission,
or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company or any of
its subsidiaries (or, to the Company&rsquo;s knowledge, any other entity for whose acts or omissions the Company or any of its
subsidiaries is or may otherwise be liable) upon any of the property now or previously owned or leased by the Company or any of its
subsidiaries, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment, decree or
permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment, decree
or permit, give rise to any liability, except for any violation or liability which has not had and would not reasonably be expected
to have, singularly or in the aggregate with all such violations and liabilities, a Material Adverse Effect; and there has been no
disposal, discharge, emission or other release of any kind onto such property or into the environment surrounding such property of
any toxic or other wastes or other hazardous substances with respect to which the Company or any of its subsidiaries has knowledge,
except for any such disposal, discharge, emission, or other release of any kind which would not have, singularly or in the aggregate
with all such discharges and other releases, a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(z) <U>Intellectual
Property</U>. The Company and each of its subsidiaries own or possess or have valid rights to use all patents, patent applications,
trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, inventions, trade
secrets and similar rights (&ldquo;<U>Intellectual Property Rights</U>&rdquo;) necessary for the conduct of the business of the
Company and its subsidiaries as currently carried on and as described in the SEC Reports, except as would not be reasonably likely
to result in a Material Adverse Effect. To the knowledge of the Company, no action or use by the Company or any of its subsidiaries
necessary for the conduct of their business as currently carried on and as described in the SEC Reports will involve or give rise to
any infringement of, or license or similar fees for, any Intellectual Property Rights of others, except where such action, use,
license or fee is not reasonably likely to result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries have
received any notice alleging any such infringement, fee or conflict with asserted Intellectual Property Rights of others. Except as
would not reasonably be expected to result, individually or in the aggregate, in a Material Adverse Effect (A) to the knowledge of
the Company, there is no infringement, misappropriation or violation by third parties of any of the Intellectual Property Rights
owned by the Company or any of its subsidiaries; (B) there is no pending or, to the knowledge of the Company, threatened action,
suit, proceeding or claim by others challenging the rights of the Company or any of its subsidiaries in or to any such Intellectual
Property Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim, that would,
individually or in the aggregate, together with any other claims in this Section 3.1(t), reasonably be expected to result in a
Material Adverse Effect; (C) the Intellectual Property Rights owned by the Company or any of its subsidiaries and, to the knowledge
of the Company, the Intellectual Property Rights licensed to the Company have not been adjudged by a court of competent jurisdiction
invalid or unenforceable, in whole or in part, and there is no pending or, to the Company&rsquo;s knowledge, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property Rights, and the Company is
unaware of any facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together
with any other claims in this Section 3.1(t), reasonably be expected to result in a Material Adverse Effect; (D) there is no pending
or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that the Company or any of its
subsidiaries infringes, misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of
others, neither the Company nor any of its subsidiaries has received any written notice of such claim and the Company is unaware of
any other facts which would form a reasonable basis for any such claim that would, individually or in the aggregate, together with
any other claims in this Section 3.1(t), reasonably be expected to result in a Material Adverse Effect; and (E) except as disclosed
in the SEC Reports, to the Company&rsquo;s knowledge, no employee of the Company or any of its subsidiaries is in or has ever been
in violation in any material respect of any term of any employment contract, patent disclosure agreement, invention assignment
agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a
former employer where the basis of such violation relates to such employee&rsquo;s employment with the Company or any of its
subsidiaries, or actions undertaken by the employee while employed with the Company or any of its subsidiaries and could reasonably
be expected to result, individually or in the aggregate, in a Material Adverse Effect. To the Company&rsquo;s knowledge, all
material technical information developed by and belonging to the Company or any of its subsidiaries which has not been patented has
been kept confidential. Neither the Company nor any of its subsidiaries is a party to or bound by any options, licenses or
agreements with respect to the Intellectual Property Rights of any other person or entity that are required to be set forth in the
SEC Reports and are not described therein. The SEC Reports contain in all material respects the same description of the matters set
forth in the preceding sentence. None of the technology employed by the Company or its subsidiaries has been obtained or is being
used by the Company or any of its subsidiaries in violation of any contractual obligation binding on the Company or any such
subsidiary or, to the Company&rsquo;s knowledge, any of its or its subsidiaries&rsquo; officers, directors or employees, or
otherwise in violation of the rights of any persons, except for violations that would not result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(aa) <U>Brokers</U>.
Neither the Company nor any of its subsidiaries is a party to any contract, agreement or understanding with any person (other than as
contemplated by this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or the Purchaser
for a brokerage commission, finder&rsquo;s fee or like payment in connection with the offering and sale of the Securities under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(bb) <U>No Outstanding
Loans or Other Indebtedness</U>. There are no outstanding loans, advances (except normal advances for business expenses in the ordinary
course of business) or guarantees or indebtedness by the Company or any of its subsidiaries to or for the benefit of any of the officers
or directors of the Company or executive officers of any of its subsidiaries to the extent such executive officers may be deemed executive
officers of the Company, or any of their respective family members, except as disclosed in the SEC Reports. The Company has not directly
or indirectly extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit, in the form of a
personal loan to or for any director or executive officer of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(cc) <U>Broker-Dealer
Status</U>. Neither the Company nor any of its related entities (i) is required to register as a &ldquo;broker&rdquo; or &ldquo;dealer&rdquo;
in accordance with the provisions of the Exchange Act or (ii) directly or indirectly through one or more intermediaries, controls or is
a &ldquo;person associated with a member&rdquo; or &ldquo;associated person of a member&rdquo; (within the meaning of Article I of the
NASD Manual administered by FINRA). To the Company&rsquo;s knowledge, there are no affiliations or associations between any member of FINRA
and any of the Company&rsquo;s officers, directors or 5% or greater security holders, except as set forth in the SEC Reports.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(dd) <U>Form
S-3 Eligibility</U>. The Company meets the applicable requirements for use of Form S-3 under the Securities Act, including compliance
with General Instruction I.B.1 or General Instruction I.B.6 of Form S-3, if and for so long as applicable. The Company is not a shell
company (as defined in Rule 405 under the Securities Act) and has not been a shell company for at least 12 calendar months previously
and if it has been a shell company at any time previously, has filed current Form 10 information (as defined in General Instruction I.B.6
of Form S-3) with the Commission at least 12 calendar months previously reflecting its status as an entity that is not a shell company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(ee) <U>Compliance
with Orders</U>. Neither the Company nor any of its subsidiaries is in violation of any material judgment, decree, or order of any court,
arbitrator or other governmental authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(ff) <U>Sarbanes-Oxley
Act</U>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities
as such, to comply in all material respects with any applicable provision of the Sarbanes-Oxley Act of 2002 and the rules and regulations
promulgated in connection therewith (the &ldquo;<U>Sarbanes-Oxley Act</U>&rdquo;), including Section 402 related to loans and Sections
302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(gg) <U>Disclosure
Controls and Procedures</U>. Except as set forth in the SEC Reports, the Company and its subsidiaries maintain systems of
&ldquo;internal control over financial reporting&rdquo; (as defined under Rules 13a-15 and 15d-15 under the Exchange Act) that
comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal
executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP,
including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i) transactions are
executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is
permitted only in accordance with management&rsquo;s general or specific authorization; (iv) the recorded accountability for assets
is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(v) the interactive data in eXtensible Business Reporting Language included or incorporated by reference in the SEC Reports fairly
present the information called for in all material respects and are prepared in accordance with the Commission&rsquo;s rules and
guidelines applicable thereto. Since the date of the latest audited financial statements included in the SEC Reports, there has been
no change in the Company&rsquo;s internal control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(hh) <U>ERISA</U>.
The Company, its subsidiaries and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee Retirement Income Security
Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;ERISA&rdquo;))
established or maintained by the Company, its subsidiaries or any of their &ldquo;ERISA Affiliates&rdquo; (as defined below) are in
compliance in all material respects with ERISA. &ldquo;ERISA Affiliate&rdquo; means, with respect to the Company and each of its
subsidiaries, any member of any group of organizations described in Sections 414(b),(c),(m) or (o) of the Internal Revenue Code of
1986, as amended, and the regulations and published interpretations thereunder (the &ldquo;Code&rdquo;) of which the Company or any
of its subsidiaries is a member. No &ldquo;reportable event&rdquo; (as defined under ERISA) has occurred or is reasonably expected
to occur with respect to any &ldquo;employee benefit plan&rdquo; established or maintained by the Company, or any of its
subsidiaries or any of their ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established or maintained by the Company, any
of its subsidiaries or any of their ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were terminated, would have any
&ldquo;amount of unfunded benefit liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its subsidiaries nor
any of their ERISA Affiliates has incurred or reasonably expects to incur any material liability under (i) Title IV of ERISA with
respect to termination of, or withdrawal from, any &ldquo;employee benefit plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of
the Code. Each &ldquo;employee benefit plan&rdquo; established or maintained by the Company, any of its subsidiaries or any of their
ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to the knowledge of the
Company, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(ii) <U>Contracts
and Agreements</U>. The agreements and documents described in the SEC Reports conform in all material respects to the descriptions thereof
contained therein and there are no agreements or other documents required by the Securities Act and the Exchange Act to be described in
the SEC Reports or to be filed with the Commission as exhibits to the SEC Reports, that have not been so described or filed. Each agreement
or other instrument (however characterized or described) to which the Company or any of its subsidiaries is a party or by which it is
or may be bound or affected and (i) that is referred to in the SEC Reports, or (ii) is material to the Company&rsquo;s or its subsidiaries&rsquo;
business, has been duly authorized and validly executed by the Company, is in full force and effect in all material respects and is enforceable
against the Company or any of its subsidiaries and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance with its
terms, except (x) as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo;
rights generally, (y) as enforceability of any indemnification or contribution provision may be limited under the federal and state securities
laws, and (z) that the remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable
defenses and to the discretion of the court before which any proceeding therefor may be brought. Except as disclosed in the SEC Reports,
none of such agreements or instruments has been assigned by the Company or its subsidiaries, and neither the Company, its subsidiaries
nor, to the Company&rsquo;s knowledge, any other party is in default thereunder and, to the Company&rsquo;s knowledge, no event has occurred
that, with the lapse of time or the giving of notice, or both, would constitute a default thereunder. To the Company&rsquo;s knowledge,
performance by the Company or any of its subsidiaries of the material provisions of such agreements or instruments will not result in
a violation of any existing applicable law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic
or foreign, having jurisdiction over the Company, its subsidiaries or any of their assets or businesses (each, a &ldquo;<U>Governmental
Entity</U>&rdquo;), including, without limitation, those relating to environmental laws and regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">(jj) <U>Title to
Properties</U>. Except as set forth in the SEC Reports, the Company and each of its subsidiaries have good and marketable title in
fee simple to, or have valid rights to lease or otherwise use, all items of real or personal property which are material to the
business of the Company, in each case free and clear of all liens, encumbrances, security interests, claims and defects that do not,
singly or in the aggregate, materially affect the value of such property and do not interfere with the use made and proposed to be
made of such property by the Company or any of its subsidiaries; and all of the leases and subleases material to the business of the
Company, and under which the Company or any of its subsidiaries hold properties described in the SEC Reports, are in full force and
effect, and neither the Company nor any of its subsidiaries has received any notice of any material claim of any sort that has been
asserted by anyone adverse to the rights of the Company or any of its subsidiaries under any of the leases or subleases mentioned
above, or affecting or questioning the rights of the Company or any of its subsidiaries to the continued possession of the leased or
subleased premises under any such lease or sublease, which would result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(kk) <U>No Unlawful
Contributions or Other Payments</U>. No payments or inducements have been made or given, directly or indirectly, to any federal or local
official or candidate for, any federal or state office in the United States or foreign offices by the Company, any of its subsidiaries
or any of their officers or directors, or, to the knowledge of the Company, by any of its employees or agents or any other person in connection
with any opportunity, contract, permit, certificate, consent, order, approval, waiver or other authorization relating to the business
of the Company or any of its subsidiaries, except for such payments or inducements as were lawful under applicable laws, rules and regulations.
Neither the Company, any of its subsidiaries, nor, to the knowledge of the Company, any director, officer, agent, employee or other person
associated with or acting on behalf of the Company or any of its subsidiaries, (i) has used any corporate funds for any unlawful contribution,
gift, entertainment or other unlawful expense relating to political activity; (ii) made any direct or indirect unlawful payment to any
government official or employee from corporate funds; or (iii) made any bribe, unlawful rebate, payoff, influence payment, kickback or
other unlawful payment in connection with the business of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(ll) <U>Foreign
Corrupt Practices Act</U>. None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent,
employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries, is aware of or has taken any action, directly
or indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules
and regulations thereunder (collectively, the &ldquo;<U>FCPA</U>&rdquo;), including, without limitation, making use of the mails or any
means or instrumentality of interstate commerce corruptly in furtherance of an offer, payment, promise to pay or authorization of the
payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any &ldquo;foreign
official&rdquo; (as such term is defined in the FCPA) or any foreign political party or official thereof or any candidate for foreign
political office, in contravention of the FCPA. The Company and its subsidiaries have conducted their respective businesses in compliance
with the FCPA and have instituted and maintains policies and procedures designed to ensure, and which are reasonably expected to continue
to ensure, continued compliance therewith. The foregoing representation and warranty shall also be deemed given regarding laws of applicable
non-U.S. jurisdictions similar to the FCPA, including, without limitation, Sections 291 and 291A of the Israel Penal Law, 5737-1977 and
the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(mm) <U>Money
Laundering Laws</U>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance with applicable
financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money
laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations or guidelines,
issued, administered or enforced by any governmental agency (collectively, the &ldquo;Money Laundering Laws&rdquo;) and no action, suit
or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries
with respect to the Money Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(nn) <U>OFAC</U>.
None of the Company, any of its subsidiaries or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or
person acting on behalf of the Company or any of its subsidiaries is currently subject to any U.S. sanctions administered by the Office
of Foreign Assets Control of the U.S. Treasury Department (&ldquo;<U>OFAC</U>&rdquo;); and the Company will not directly or indirectly
use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner
or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered
by OFAC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(oo) <U>Exchange
Listing</U>. The Common Shares are registered pursuant to Section 12(b) of the Exchange Act and are currently listed on the Trading Market
under the trading symbol &ldquo;PLUR&rdquo;. Except as disclosed in the SEC Reports, there is no action pending by the Company or, to
the Company&rsquo;s knowledge, the Trading Market to delist the Common Shares from the Trading Market, nor has the Company received any
notification that the Trading Market is currently contemplating terminating such listing, except as otherwise disclosed in the SEC Reports.
The Company has no intention to delist the Common Shares from the Trading Market or to deregister the Common Shares under the Exchange
Act. The Company shall file, to the extent required, (i) with the Nasdaq a Supplemental Listing Application for the listing of the Common
Shares and the Warrant shares as contemplated in this Agreement, and (ii) with the Tel Aviv Stock Exchange an application for the listing
of the Common Shares and the Warrant Shares as contemplated in this Agreement. The issuance and sale of the Securities under this Agreement
does not contravene the rules and regulations of the Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(pp) <U>Margin
Rules</U>. The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation U of the Board of Governors of the
Federal Reserve System (the &ldquo;<U>Federal Reserve Board</U>&rdquo;), and none of the proceeds from the issuance, sale and delivery
of the Securities as contemplated by this Agreement and as described in the SEC Reports will be used, directly or indirectly, for the
purpose of purchasing or carrying any margin security, for the purpose of reducing or retiring any indebtedness which was originally incurred
to purchase or carry any margin security or for any other purpose which might cause any of the Common Shares to be considered a &ldquo;purpose
credit&rdquo; within the meanings of Regulation T, U or X of the Federal Reserve Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(qq) <U>Board
of Directors</U>. The qualifications of the persons serving as board members of the Company and the overall composition of the Company&rsquo;s
Board of Directors comply with the applicable requirements of the Exchange Act and the Sarbanes-Oxley Act and the listing rules of the
Exchange applicable to the Company. At least one member of the Audit Committee of the Board of Directors of the Company
qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined under Regulation S-K and the listing rules of
the Exchange. In addition, at least a majority of the persons serving on the Board of Directors of the Company qualify as &ldquo;independent,&rdquo;
as defined under the listing rules of the Exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(rr) <U>No Integration</U>.
Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf has, directly or indirectly, made any offers
or sales of any security or solicited any offers to buy any security, under circumstances that would cause the offer and sale of the Securities
hereunder to be integrated with prior offerings by the Company for purposes of the Securities Act that would require the registration
of the Securities or any such other securities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(ss) <U>No Material
Defaults</U>. Neither the Company nor any of its subsidiaries has defaulted on any installment on indebtedness for borrowed money or on
any rental on one or more long-term leases, which defaults, individually or in the aggregate, could reasonably be expected to result in
a Material Adverse Effect. The Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing
of its last Annual Report on Form 10-K, indicating that it (i) has failed to pay any dividend or sinking fund installment on preferred
shares or (ii) has defaulted on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which
defaults, individually or in the aggregate, could reasonably be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(tt) <U>Books
and Records</U>. The minute books of the Company and each of its subsidiaries (i) contain a substantially complete summary of all meetings
and material actions of the board of directors (including each board committee) and shareholders of the Company (or analogous governing
bodies and interest holders, as applicable) and each of its subsidiaries since the time of its respective incorporation or organization
through the date of the latest meeting and action, and (ii) accurately reflects in all material respects all transactions referred to
in such minutes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(uu) <U>Regulations</U>.
The disclosures in the SEC Reports concerning the effects of federal, state, local and all foreign regulation on the Company&rsquo;s business
in the past and as currently contemplated are correct in all material respects and no other such regulations are required to be disclosed
in the SEC Reports which are not so disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(vv) <U>Regulatory
Matters; Compliance</U>. The material terms of all preclinical and other nonclinical studies and clinical trials conducted by or on behalf
of the Company that are material to the Company have been adequately described in the SEC Reports, in all material respects. The clinical
trials and nonclinical studies conducted by or on behalf of the Company that are described in the SEC Reports or the results of such trials
and studies which are referred to in the SEC Reports were and, if still ongoing, are being conducted in material compliance with all laws
and regulations applicable thereto in the jurisdictions in which they are being conducted. The descriptions in the SEC Reports of the
results of such trials and studies are accurate and complete in all material respects and fairly present the data derived from such trials
and studies, and the Company has no knowledge of any clinical trials the aggregate results of which are inconsistent with or otherwise
call into question the results of any clinical trial conducted by or on behalf of the Company that are described in the SEC Reports or
the results of which are referred to in the SEC Reports. Except as disclosed
in the SEC Reports, the Company has not received any written notices or other communications from the FDA, the European Medicines Agency
(&ldquo;<U>EMA</U>&rdquo;) or any other governmental agency or authority imposing, requiring, requesting or suggesting a clinical hold,
termination, suspension or material modification of any clinical trial that is described in the SEC Reports or the results of which are
referred to in the SEC Reports. Except as disclosed in the SEC Reports, the Company has not received any written notices or other communications
from the FDA, the EMA or any other governmental agency, and otherwise has no knowledge of, or reason to believe that, (i) any investigational
new drug application for a potential product of the Company is or has been rejected or determined to be non-approvable or conditionally
approvable; and (ii) any license, approval, permit or authorization to conduct any clinical trial of any potential product of the Company
has been, will be or may be suspended, revoked, modified or limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(ww) <U>Information
Technology</U>. The Company&rsquo;s information technology assets and equipment, computers, systems, networks, hardware, software, websites,
applications, and databases (collectively, &ldquo;<U>IT Systems</U>&rdquo;) are adequate for, and operate and perform in all material
respects as required in connection with, the operation of the business of the Company as currently conducted, except where such failure
to operate and perform would not reasonably be expected to result in a Material Adverse Effect, and to the knowledge of the Company are
free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. The Company has implemented
and maintained commercially reasonable controls, policies, procedures, and safeguards to maintain and protect their material confidential
information and the integrity, continuous operation, redundancy and security of all IT Systems and data (including all personal, personally
identifiable, sensitive, confidential or regulated data (&ldquo;<U>Personal Data</U>&rdquo;)) used in connection with their businesses,
and except as would not, individually or in the aggregate, result in a Material Adverse Effect, there have been no breaches, violations,
outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability or the
duty to notify any other person, nor any incidents under internal review or investigations relating to the same. The Company is presently
in compliance in all material respects with all applicable laws or statutes and all applicable judgments, orders, rules and regulations
of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy
and security of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access,
misappropriation or modification, except for any such noncompliance that would not result in a Material Adverse Effect. The disclosures
in the SEC Reports concerning the effects of federal, state, local and all foreign regulation on the Company&rsquo;s business in the past
and as currently contemplated are correct in all material respects and no other such regulations are required to be disclosed in the SEC
Reports which are not so disclosed. The Company has taken all reasonably necessary actions to comply materially with the European Union
General Data Protection Regulation and all other applicable laws and regulations with respect to Personal Data that have been announced
as of the date hereof as becoming effective within 12 months after the date hereof, and for which any non-compliance with same would be
reasonably likely to create a material liability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(xx) <U>Confidentiality
and Non-Competition</U>. To the Company&rsquo;s knowledge, no director, officer, key employee or consultant of the Company is
subject to any confidentiality, non-disclosure, non-competition agreement or non-solicitation agreement with any employer or prior
employer that could reasonably be expected to materially affect his ability to be and act in his respective capacity of the Company
or be expected to result in a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(yy) <U>All Necessary
Permits, etc.</U> The Company and each of its subsidiaries holds, and is in compliance with, all franchises, grants, authorizations, licenses,
permits, easements, consents, certificates and orders (&ldquo;<U>Permits</U>&rdquo;) of any governmental or self-regulatory agency, authority
or body required for the conduct of its business, and all such Permits are in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">3.2 <U>Representations
and Warranties of the Purchaser</U>. The Purchaser hereby represents and warrants as of the date hereof and as of the Closing Date to
the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(a) <U>Organization;
Authority</U>. The Purchaser is either an individual or an entity duly incorporated or formed, validly existing and in good standing under
the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar
power and authority to enter into and to consummate the transactions contemplated by the Transaction Documents and otherwise to carry
out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by the Purchaser
of the transactions contemplated by the Transaction Documents have been duly authorized by all necessary corporate, partnership, limited
liability company or similar action, as applicable, on the part of the Purchaser. Each Transaction Document to which it is a party has
been duly executed by the Purchaser, and when delivered by the Purchaser in accordance with the terms hereof, will constitute the valid
and legally binding obligation of the Purchaser, enforceable against it in accordance with its terms, except: (i) as limited by general
equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting
enforcement of creditors&rsquo; rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive
relief or other equitable remedies and (iii) insofar as indemnification and contribution provisions may be limited by applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(b) <U>Understandings
or Arrangements</U>. The Purchaser understands that the Securities are &ldquo;restricted securities&rdquo; and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Securities as principal for its own account and not
with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable
state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable
state securities law and has no direct or indirect arrangement or understandings with any other persons to distribute or regarding the
distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty
not limiting the Purchaser&rsquo;s right to sell the Securities in compliance with applicable federal and state securities laws). The
Purchaser is acquiring the Securities hereunder in the ordinary course of its business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(c) <U>Experience
of the Purchaser</U>. The Purchaser, either alone or together with its representatives, has such knowledge, sophistication and experience
in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities,
and has so evaluated the merits and risks of such investment. The Purchaser is able to bear the economic risk of an investment in the
Securities and, at the present time, is able to afford a complete loss of such investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt"><FONT STYLE="font-size: 10pt">(d) <U>Access
to Information</U>. The Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including all exhibits
and schedules thereto) and the SEC Reports and has been afforded, (i) the opportunity to ask such questions as it has </FONT>deemed necessary
of, and to receive answers from, representatives of the Company concerning the terms and conditions of the offering of the Securities
and the merits and risks of investing in the Securities; (ii) access to information about the Company and its financial condition, results
of operations, business, properties, management and prospects sufficient to enable it to evaluate its investment; and (iii) the opportunity
to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary
to make an informed investment decision with respect to the investment</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(e) <U>Certain
Transactions and Confidentiality</U>. Other than consummating the transactions contemplated hereunder, the Purchaser has not, nor has
any Person acting on behalf of or pursuant to any understanding with the Purchaser, directly or indirectly executed any purchases or sales,
including Short Sales, of the securities of the Company during the period commencing as of the time that the Purchaser first received
a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material terms of the transactions
contemplated hereunder and ending immediately prior to the execution hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(f) <U>Non-Interference
with Company&rsquo;s Business</U>. The Purchaser has reviewed the SEC Reports, is familiar with the Company&rsquo;s business, has no intention
to act to change the Company&rsquo;s business and will not be acting to change the Company&rsquo;s business without the consent of the
Company&rsquo;s board of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(g) <U>Purchaser
Status</U>. At the time the Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it
exercises any Warrants, it will be a &ldquo;non-US person&rdquo; as defined in Regulation S (&ldquo;<U>Regulation S</U>&rdquo;) as promulgated
under the Securities Act and/or an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(h) <U>General
Solicitation</U>. The Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented at any
seminar or, to the knowledge of the Purchaser, any other general solicitation or general advertisement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 51.1pt">(i) <U>Purchaser
reporting obligations</U>. Purchaser acknowledges that as a result of the purchase of the Shares, Purchaser may be subject to the reporting
obligations of Section 13 and Section 16 of the Exchange Act, and Purchaser agrees to comply with all such reporting obligations in a
timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company acknowledges and agrees
that the representations contained in this Section 3.2 shall not modify, amend or affect the Purchaser&rsquo;s right to rely on the Company&rsquo;s
representations and warranties contained in this Agreement or any representations and warranties contained in any other Transaction Document
or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions
contemplated hereby. Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation
or warranty, or preclude any actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE IV.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">OTHER AGREEMENTS OF THE PARTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> 4.1 <U>Transfer Restrictions</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(a) <FONT STYLE="font-size: 10pt">The
Securities may only be disposed of in compliance with U.S. state and U.S. federal securities laws. In connection with any transfer of
Securities other than pursuant to an effective Registration Statement (as contemplated by Section 4.10 or otherwise) or Rule 144, to the
Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section 4.1(b), the Company may require the
transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company,
the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require
registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall agree in writing
to be bound by the terms of this Agreement and shall have the rights and obligations of a Purchaser under this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(b) <FONT STYLE="font-size: 10pt">The
Purchaser agrees to the imprinting, so long as required by this Section 4.1, of a legend on the Securities substantially in the following
form (in addition to any legend required by applicable state securities or &ldquo;blue sky&rdquo; laws):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-left: 0.5in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;[NEITHER] THIS SECURITY
[NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE] HAS [NOT] BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&ldquo;<U>SECURITIES ACT</U>&rdquo;), OR ANY STATE SECURITIES LAWS AND MAY NOT BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF UNLESS REGISTERED
UNDER THE SECURITIES ACT AND UNDER APPLICABLE STATE SECURITIES LAWS OR THE COMPANY SHALL HAVE RECEIVED AN OPINION OF COUNSEL THAT REGISTRATION
OF SUCH SECURITIES [AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY] UNDER THE SECURITIES ACT AND UNDER THE PROVISIONS OF APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Each certificate
representing the Securities, if such securities are being offered to the Purchaser in reliance upon Regulation S, shall be stamped or
otherwise imprinted with a legend substantially in the following form (in addition to any legend required by applicable state securities
or &ldquo;blue sky&rdquo; laws):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;[NEITHER] THIS SECURITY
[NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE] HAS [NOT] BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
&ldquo;SECURITIES ACT&rdquo;), OR ANY STATE SECURITIES LAWS AND NEITHER SUCH SECURITIES [AND THE SECURITIES ISSUABLE UPON EXERCISE OF
THIS SECURITY] NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED EXCEPT (1) IN ACCORDANCE WITH
THE PROVISIONS OF REGULATION S PROMULGATED UNDER THE SECURITIES ACT, AND BASED ON AN OPINION OF COUNSEL, WHICH COUNSEL AND OPINION ARE
REASONABLY SATISFACTORY TO THE COMPANY, THAT THE PROVISIONS OF REGULATION S HAVE BEEN SATISFIED, (2) PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS OR (3) PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION
REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS, IN WHICH CASE THE HOLDER MUST, PRIOR TO SUCH TRANSFER, FURNISH
TO THE COMPANY AN OPINION OF COUNSEL, WHICH COUNSEL AND OPINION ARE REASONABLY SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES [OR THE
SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY] MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR OTHERWISE TRANSFERRED IN THE MANNER CONTEMPLATED
PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS. HEDGING
TRANSACTIONS INVOLVING THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">4.2 <U>Securities
Laws Disclosure; Publicity</U>. The Company (a) shall, by the Disclosure Time issue a press release disclosing the material terms of the
transactions contemplated hereby, and (b) shall file a Current Report on Form 8-K, including the Transaction Documents as exhibits thereto,
with the Commission within the time required by the Exchange Act. Purchaser shall be afforded the right to review and comment on the draft
press release and Form 8-K sufficiently in advance of the Disclosure Time, and, subject to applicable law, the Company shall favorably
consider including all comments provided by Purchaser. From and after the issuance of such press release, the Company represents to the
Purchaser that it shall have publicly disclosed all material, non-public information delivered to the Purchaser by the Company or any
of its Subsidiaries, or any of their respective officers, directors, employees or agents in connection with the transactions contemplated
by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that
any and all confidentiality or similar obligations under any agreement, whether written or oral, between the Company, any of its Subsidiaries
or any of their respective officers, directors, agents, employees or Affiliates on the one hand, and the Purchaser or any of its Affiliates
on the other hand, shall terminate. The Company and the Purchaser shall consult with each other in issuing any other press releases with
respect to the transactions contemplated hereby, and neither the Company nor the Purchaser shall issue any such press release nor otherwise
make any such public statement without the prior consent of the Company, with respect to any press release of the Purchaser, or without
the prior consent of the Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld
or delayed, except if such disclosure is required by law, in which case the disclosing party shall promptly provide the other party with
prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name
of the Purchaser, or include the name of the Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without
the prior written consent of the Purchaser, except (a) as required by federal securities law in connection with the filing of final Transaction
Documents with the Commission and (b) to the extent such disclosure is required by law or Trading Market regulations, in which case the
Company shall provide the Purchaser with prior notice of such disclosure permitted under this clause (b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">4.3 <U>Certain
Transactions and Confidentiality</U>. The Purchaser covenants that neither it nor any Affiliate acting on its behalf or pursuant to
any understanding with it will execute any purchases or sales, including Short Sales of any of the Company&rsquo;s securities during
the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section 4.2. The Purchaser covenants
that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the
initial press release as described in Section 4.2, the Purchaser will maintain the confidentiality of the existence and terms of
such transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">4.4 <U>Form
D; Blue Sky Filings</U>. The Company agrees to timely file a Form D, if required by applicable law, with respect to the Securities as
may be required under Regulation D and to provide a copy thereof, promptly upon request of the Purchaser. The Company shall take such
action as the Company shall reasonably determine is necessary in order to obtain an exemption for, or to qualify the Shares for sale to
the Purchaser at the Closing under applicable securities or &ldquo;Blue Sky&rdquo; laws of the states of the United States, if necessary,
and shall provide evidence of such actions promptly upon request of the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> 4.5 [Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">4.6 <U>Transfer
Taxes</U>. On the Closing Date, all stock transfer, stamp or other taxes (other than income taxes) that are required to be paid in connection
with the issuance, sale and delivery of the Securities to the Purchaser hereunder will be fully paid or provided for by the Company and
all laws imposing such taxes will have been fully complied with and the Purchasers and their respective Affiliates shall have no obligation
therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">4.7 <U>Reservation
of Common Shares</U>. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available at
all times, free of preemptive rights, a sufficient number of Common Shares for the purpose of enabling the Company to issue the Warrant
Shares that are issuable upon the exercise of the Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: -35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"> 4.8 <U>[Reserved].</U></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">4.9 <U>Adjustments
in Share Numbers and Prices</U>. In the event of any share split, subdivision, dividend or distribution payable in Common Shares (or other
securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly Common Shares), combination or
other similar recapitalization or event occurring after the date hereof and prior to the Closing, each reference this Agreement to a number
of shares or a price per share shall be deemed to be amended to appropriately account for such event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">4.10 <U>Rule
144 Information</U>. The Company shall use its reasonable best efforts to timely file all reports required under the Exchange Act so as
to enable the Purchaser to sell the Shares and Warrant Shares pursuant to Rule 144, if applicable. </FONT>.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ARTICLE V.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">MISCELLANEOUS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.1 <U>Termination</U>.
This Agreement may be terminated by the Company or the Purchaser by written notice to the other party, if the Closing has not been consummated
on or before December 24, 2025; <U>provided</U>, <U>however</U>, that no such termination will affect the right of any party to sue for
any breach by any other party (or parties).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.2 <U>Fees
and Expenses</U>. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for same-day processing
of any instruction letter delivered by the Company and any exercise notice delivered by a Purchaser), fees and expenses in connection
with the TASE and Nasdaq listing, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the
Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.3 <U>Entire
Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of the parties
with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect
to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.4 <U>Notices</U>.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and shall
be deemed given and effective on the earliest of: (a) the time of transmission, if such notice or communication is delivered via email
attachment at the email address as set forth on the signature pages attached hereto at or prior to 5:30 p.m. (New York City time) on a
Trading Day, (b) the next Trading Day after the time of transmission, if such notice or communication is delivered via facsimile at the
facsimile number or email attachment at the email address as set forth on the signature pages attached hereto on a day that is not a Trading
Day or later than 5:30 p.m. (New York City time) on any </FONT>Trading Day, (c) the second (2<SUP>nd</SUP>) Trading Day following the
date of mailing, if sent by U.S. nationally recognized overnight courier service or (d) upon actual receipt by the party to whom such
notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages attached
hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, non-public information
regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the Commission pursuant to a Current
Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.5 <U>Amendments;
Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument signed, in
the case of an amendment, by the Company and the Purchaser. No waiver of any default with respect to any provision, condition or requirement
of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other
provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner
impair the exercise of any such right. Any amendment effected in accordance with this Section 5.5 shall be binding upon the Purchaser
and holder of Securities and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.6 <U>Headings</U>.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any
of the provisions hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.7 <U>Successors
and Assigns</U>. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns.
The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Purchaser (other
than by merger). The Purchaser may assign any or all of its rights under this Agreement to any Person to whom the Purchaser assigns or
transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by
the provisions of the Transaction Documents that apply to the Purchaser.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.8 <U>No
Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in
this Section 5.8.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">5.9 <U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts
of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates,
directors, officers, shareholders, partners, members, employees or agents) shall be commenced exclusively in the state and federal courts
sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the City of New York, Borough of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any action or proceeding, any claim that it </FONT>is not personally subject to the jurisdiction of
any such court, that such action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such action or proceeding by mailing a copy thereof via
registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it
under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If any party shall
commence an action or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action or proceeding
shall be reimbursed by the non-prevailing party for its reasonable attorneys&rsquo; fees and other costs and expenses incurred with the
investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.10 <U>Survival</U>.
The representations and warranties of the Purchaser and the agreements and covenants contained herein shall survive the Closing and the
delivery of the Shares for a period of two (2) years from the Closing. The agreements and covenants contained herein shall survive for
the applicable statute of limitations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.11 <U>Execution</U>.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement
and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that
the parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by e-mail delivery
of a &ldquo;.pdf&rdquo; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose
behalf such signature is executed) with the same force and effect as if such facsimile or &ldquo;.pdf&rdquo; signature page were an original
thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.12 <U>Severability</U>.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid, illegal,
void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force
and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially reasonable efforts
to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision,
covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would have executed the remaining
terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.13 <U>Independent
Nature of Purchaser&rsquo;s Obligations and Rights</U>. Nothing contained herein or in any other Transaction Document, and no action taken
by the Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchaser as a partnership, an association, a joint venture
or any other kind of entity, or create a presumption that the Purchaser is in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated by the Transaction Documents. The Purchaser shall be entitled to independently protect
and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents.
The Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.14 <U>Fridays,
Satrudays, Sundays, Holidays, etc.</U> If the last or appointed day for the taking of any action or the expiration of any right required
or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">5.15 <U>Construction</U>.
The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise the Transaction Documents
and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall
not be employed in the interpretation of the Transaction Documents or any amendments thereto. In addition, each and every reference to
share prices and Common Shares in any Transaction Document shall be subject to adjustment for reverse and forward share splits, share
dividends, share combinations and other similar transactions of the Common Shares that occur after the date of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal; text-decoration: none">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">5.16 <U>WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY
AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVES
FOREVER TRIAL BY JURY.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Pages Follow)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of
the date first indicated above.</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%"><B>PLURI INC.</B></TD>
  <TD STYLE="width: 40%"><U>Address for Notice:</U></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>MATAM Advanced Technology</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Park Building No. 5</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Haifa, Israel 3508409</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"> <FONT STYLE="text-decoration: none">/s/ Yaky Yanay</FONT></TD>
    <TD>&nbsp;</TD>
  <TD>E-mail: yaky@pluri-biotech.com</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 6%">Name:&nbsp;</TD>
  <TD STYLE="width: 30%">Yaky Yanay</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By:</TD>
  <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="text-decoration: none">/s/ Liat Zalts</FONT></TD>
    <TD>&nbsp;</TD>
  <TD>E-mail: liat.zalts@pluri-biotech.com</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 4%">&nbsp;</TD>
  <TD STYLE="width: 6%">Name:&nbsp;</TD>
  <TD STYLE="width: 30%"> Liat Zalts</TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
  <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>Title:</TD>
  <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK <BR>
SIGNATURE PAGE FOR PURCHASER FOLLOWS]</P>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0pt; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[PURCHASER SIGNATURE PAGES TO SECURITIES PURCHASE AGREEMENT]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF,
the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the
date first indicated above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>U.S. Domestic Purchaser (please check): &#9744;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Non-U.S. Purchaser (please check): </B> <U></U>&#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Name of Purchaser: <U>Chutzpah Holdings LP</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature of Authorized Signatory of Purchaser: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">/s/ Alexandre Weinstein</U></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">Alexandre Weinstein</U></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory: &nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Email Address of Authorized Signatory: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U STYLE="text-decoration: none">alexandre@bechutzpah.ch</U></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Address for Notice to Purchaser: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">337 WINSTON ROAD OAKVILLE<BR>
 Ontario (CA-ON), L6L <BR>
4W6 CANADA</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Subscription Amount: <U>$2,500,000</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Number of Shares: <U>625,000</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Common Warrant: <U>625,000</U> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">EIN Number (for U.S. Domestic Purchaser): __________________________</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-variant: small-caps"><B>Form
of Warrant</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 25.65pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exhibit B-1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Accredited
Investor Questionnaire (U.S. investor only)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The undersigned
understands that the representations contained below are made for the purpose of qualifying him or her as an &ldquo;accredited investor&rdquo;
as that term is defined in Regulation D of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended
(the &ldquo;Act&rdquo;), and for the purpose of inducing a sale of the securities to him or her. The undersigned hereby represents that
the statement or statements initialed below are true and correct in all respects. The undersigned understands that a false representation
may constitute a violation of law, and that any person who suffers damage as a result of a false representation may have a claim against
the undersigned for damages.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.6in"></TD><TD STYLE="width: 0.4in">(a)</TD><TD>Accredited individual investors must initial at least one of the following statements:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in">___(1)</TD><TD STYLE="text-align: justify">I certify that I am an accredited investor because I had individual income in
excess of $200,000 in each of the two most recent years or joint income with my spouse or spousal equivalent in excess of $300,000 in
each of those years and have a reasonable expectation of reaching the same income level in the current year;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in">___(2)</TD><TD STYLE="text-align: justify">I certify that I am an accredited investor because I have an my individual net
worth, or joint net worth with my spouse and I have an individual net worth or spousal equivalent, in excess of exceeds $1,000,000. For
purposes of calculating net worth under this paragraph my primary residence is not included as an asset; indebtedness that is secured
by my primary residence, up to the estimated fair market value of the primary residence at the time of the sale of securities, is not
be included as a liability (except that if the amount of such indebtedness outstanding at the time of sale of securities exceeds the amount
outstanding 60 days before such time, other than as a result of the acquisition of the primary residence, the amount of such excess is
included as a liability); and indebtedness that is secured by my primary residence in excess of the estimated fair market value of the
primary residence at the time of the sale of securities is included as a liability.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in">___(3)</TD><TD STYLE="text-align: justify">I certify that I am an accredited investor because I am a director or executive
officer of Pluri Inc.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in">___(4)</TD><TD STYLE="text-align: justify">I hold one of the following licenses in good standing: General Securities Representative
license (Series 7), the Private Securities Offerings Representative license (Series
82), or the Investment Adviser Representative license (Series 65).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.6in"></TD><TD STYLE="width: 0.4in">(b)</TD><TD>Accredited partnerships, corporations or other entities must initial one or more of the following statements:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(1)</TD><TD STYLE="text-align: justify">The undersigned hereby certifies that all of the beneficial
equity owners of the undersigned qualify as accredited individual investors under items (a)(1) to (a)(4) above or (b)(2) to (b)(11) below;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(2)</TD><TD STYLE="text-align: justify">The undersigned is a bank as defined in section 3(a)(2) of
the Act, or any savings and loan association or other institution as defined in section 3(a)(5)(A) of the Act whether acting in its individual
or fiduciary capacity;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(3)</TD><TD STYLE="text-align: justify">The undersigned is a broker or dealer registered pursuant
to section 15 of the Securities Exchange Act of 1934, as amended;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(4)</TD><TD STYLE="text-align: justify">The undersigned is an investment adviser registered pursuant
to section 203 of the Investment Advisers Act of 1940, as amended, or registered pursuant to the laws of a state;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(5)</TD><TD STYLE="text-align: justify">The undersigned is an investment adviser relying on the exemption
from registering with the Securities and Exchange Commission under section 203(l) or (m) of the Investment Advisers Act of 1940, as amended;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(6)</TD><TD STYLE="text-align: justify">The undersigned is an insurance company as defined in section
2(a)(13) of the Act;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(7)</TD><TD STYLE="text-align: justify">The undersigned is an investment company registered under
the Investment Company Act of 1940, as amended or a business development company as defined in section 2(a)(48) of that Act;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(8)</TD><TD STYLE="text-align: justify">The undersigned is a Small Business Investment Company licensed
by the U.S. Small Business Administration under section 301(c) or (d) of the Small Business Investment Act of 1958, as amended;</TD>
</TR></TABLE>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(9)</TD><TD STYLE="text-align: justify">The undersigned is a Rural Business Investment Company as
defined in section 384A of the Consolidated Farm and Rural Development Act;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(10)</TD><TD STYLE="text-align: justify">The undersigned is a plan established and maintained by a
state, its political subdivisions, or any agency or instrumentality of a state or its political subdivisions, for the benefit of its
employees, if such plan has total assets in excess of $5,000,000;</TD>
</TR></TABLE>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(11)</TD><TD STYLE="text-align: justify">The undersigned is an employee benefit plan within the meaning
of Title I of the Employee Retirement Income Security Act of 1974 and either (check one or more, as applicable):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2.55in"></TD><TD STYLE="width: 0.55in; text-align: left">___(a)</TD><TD STYLE="text-align: justify">the investment decision is made by a plan fiduciary, as defined
therein, in Section 3(21), which is either a bank, savings and loan association, insurance company, or registered investment adviser;
or</TD>
</TR></TABLE>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2.55in"></TD><TD STYLE="width: 0.55in; text-align: left">___(b)</TD><TD STYLE="text-align: justify">the employee benefit plan has total assets in excess of $5,000,000;
or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2.55in"></TD><TD STYLE="width: 0.55in; text-align: left">___(c)</TD><TD STYLE="text-align: justify">the plan is a self-directed plan with investment decisions
made solely by persons who are &ldquo;accredited investors&rdquo; as defined therein.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(12)</TD><TD STYLE="text-align: justify">The undersigned is a private business development company
as defined in Section 202(a)(22) of the Investment Advisers Act of 1940, as amended.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(13)</TD><TD STYLE="text-align: justify">The undersigned has total assets in excess of $5,000,000,
was not formed for the specific purpose of acquiring the securities offered and is one or more of the following (check one or more, as
appropriate):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2.55in"></TD><TD STYLE="width: 0.55in; text-align: left">___(a)</TD><TD STYLE="text-align: justify">an organization described in Section 501(c)(3) of the Internal
Revenue Code of 1986, as amended;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 2.55in"></TD><TD STYLE="width: 0.55in">___(b)</TD><TD STYLE="text-align: justify">a corporation, partnership or limited liability company;</TD></TR></TABLE>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2.55in"></TD><TD STYLE="width: 0.55in; text-align: left">___(c)</TD><TD STYLE="text-align: justify">a Massachusetts or similar business trust, or</TD>
</TR></TABLE>

<P STYLE="text-indent: 0pt; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2.55in"></TD><TD STYLE="width: 0.55in; text-align: left">___(d)</TD><TD STYLE="text-align: justify">a limited liability company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(14)</TD><TD STYLE="text-align: justify">The undersigned is a trust with total assets exceeding $5,000,000,
which was not formed for the specific purpose of acquiring the securities offered and whose purchase is directed by a person who has
such knowledge and experience in financial and business matters that he or she is capable of evaluating the merits and risks of the investment
in the securities offered.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(15)</TD><TD STYLE="text-align: justify">The undersigned is an entity, of a type not listed in paragraphs
(b)(1) to (b)(14), not formed for the specific purpose of acquiring the securities offered, owning investments in excess of $5,000,000.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(16)</TD><TD STYLE="text-align: justify">The undersigned is a &ldquo;family office,&rdquo; as defined
in rule 202(a)(11)(G)-1 under the Investment Advisers Act of 1940 (17 CFR 275.202(a)(11)(G)-1): (i) with assets under management in excess
of $5,000,000, (ii) that is not formed for the specific purpose of acquiring the securities offered, and (iii) whose prospective investment
is directed by a person who has such knowledge and experience in financial and business matters that such family office is capable of
evaluating the merits and risks of the prospective investment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 2in"></TD><TD STYLE="width: 0.55in; text-align: left">___(17)</TD><TD STYLE="text-align: justify">The undersigned is a &ldquo;family client,&rdquo; as defined
in rule 202(a)(11)(G)-1 under the Investment Advisers Act of 1940 (17 CFR 275.202(a)(11)(G)-1)), of a family office meeting the requirements
in paragraph (b)(15) above and whose prospective investment in the issuer is directed by such family</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[Signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Date: ____________, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE FOR INDIVIDUAL: </FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SIGNATURE FOR PARTNERSHIP, CORPORATION, TRUST OR OTHER ENTITY:</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(signature) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of Authorized Signatory)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of any joint tenant or co-holder of any security issued by Pluri Inc.)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Authorized Signatory)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title)</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 3in">&nbsp;</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Exhibit B-2</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Regulation
S Questionnaire (Non-U.S. investor only)</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The
information contained herein is being furnished to the Company in order for the Pluri Inc. (the &ldquo;Company&rdquo;) to determine
whether the undersigned&rsquo;s subscription for Securities may be accepted pursuant to Rule 903 of Regulation S promulgated under
the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;). The undersigned understands that (i) the Company will
rely upon the following information for purposes of complying with Federal and applicable state securities laws, (ii) the Securities
will not be registered under the Securities Act in reliance upon the exemption from registration provided by Rule 903 of Regulation
S of the Securities Act, and (iii) this representation letter is not an offer to sell nor the solicitation of an offer to buy any
Securities, or any other securities, to the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-left: 2.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">At the time of (a) the offer by the Company
    and (b) the acceptance of the offer by such person or entity, of the Securities, such person or entity was outside the United
    States.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-left: 2.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Such person or entity
    is acquiring the Securities for such Purchaser&rsquo;s own account, for investment and not for distribution or resale to others and
    is not purchasing the Securities for the account or benefit of any U.S. person, or with a view towards distribution to any U.S.
    person, in violation of the registration requirements of the Securities Act.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-left: 2.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Such person or entity
will make all subsequent offers and sales of the Securities either (x) outside of the United States in compliance with Regulation S;
(y) pursuant to a registration under the Securities Act; or (z) pursuant to an available exemption from registration under the Securities
Act. Specifically, such person or entity will not resell the Securities to any U.S. person or within the United States prior to the expiration
of a period commencing on the Closing Date and ending on the date that is one year thereafter (the &ldquo;Distribution Compliance Period&rdquo;),
except pursuant to registration under the Securities Act or an exemption from registration under the Securities Act.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-left: 2.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Such person or entity has no present plan
    or intention to sell the Securities in the United States or to a U.S. person at any predetermined time, has made no predetermined
    arrangements to sell the Securities and is not acting as a distributor of such securities.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-left: 2.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Neither such person or
    entity, its affiliates nor any person acting on behalf of such person or entity, has entered into, has the intention of entering
    into, or will enter into any put option, short position or other similar instrument or position in the U.S. with respect to the
    Securities at any time after the Closing Date through the Distribution Compliance Period except in compliance with the Securities
    Act.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; padding-left: 2.5pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Such person or entity consents to the
    placement of a restrictive legend on any certificate or other document evidencing the Securities, relating to the fact that the
    Securities are not registered under the Securities Act.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">7.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-size: 10pt">Such person or entity is not acquiring
    the Securities in a transaction (or an element of a series of transactions) that is part of any plan or
scheme to evade the registration provisions of the Securities Act.</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">8.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Such person or entity has sufficient
    knowledge and experience in finance, securities, investments and other business matters to be able to protect such person&rsquo;s or
    entity&rsquo;s interests in connection with the transactions contemplated by this Agreement.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">9.</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Such person or entity has consulted, to the
    extent that it has deemed necessary, with its tax, legal, accounting and financial advisors concerning its investment in the
    Securities.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">10.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">Such person or entity
understands the various risks of an investment in the Securities and can afford to bear such risks for an indefinite period of time,
including, without limitation, the risk of losing its entire investment in the Securities.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">11.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Such person or entity
    has had access to the Company&rsquo;s publicly filed reports with the Securities and Exchange Commission and has been furnished with
    all other public information regarding the Company that such person or entity has requested and all such public information is
    sufficient for such person or entity to evaluate the risks of investing in the Securities.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">12.</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Such person or entity has been afforded the
    opportunity to ask questions of and receive answers concerning the Company and the terms and conditions of the issuance of the
    Securities.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">13.</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Such person or entity is not relying on any
    representations and warranties concerning the Company made by the Company or any officer, employee or agent of the Company, other
    than those contained in this Agreement.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">14.</FONT></TD>
    <TD>
    <P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Such person or entity will not sell or
    otherwise transfer the Securities unless either (A) the transfer of such securities is registered under the Securities Act or (B) an
    exemption from registration of such securities is available.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">15.</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Such person or entity
    understands and acknowledges that the Securities have not been recommended by any federal or state securities commission or
    regulatory authority, that the foregoing authorities have not confirmed the accuracy or determined the adequacy of any information
    concerning the Company that has been supplied to such person or entity and that any representation to the contrary is a criminal
    offense.</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[signature page follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">Date: December 8, 2025</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE FOR INDIVIDUAL:</B>
    </FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURE FOR PARTNERSHIP,
    CORPORATION, TRUST OR OTHER ENTITY:</B></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">Chutzpah Holdings LP</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(signature) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">/s/ Alexandre Weinstein</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of Authorized Signatory)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid"></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">Alexandre Weinstein</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Signature of any joint tenant or co-holder of any security issued by Pluri Inc)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Name of Authorized Signatory)</FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Print Name) </FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Title)</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt"><B>Schedule
3.1(o)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt"><B>Company Capitalization</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center; text-indent: 0.05pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>plur-20251208.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +K4ps7xRiXgOn8uBan0sSa2BacP9wZ1yqZkxvW99bbl6fyQoNF4zjSHnbfYmkZ4N -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:PLUR="http://pluri-biotech.com/20251208" elementFormDefault="qualified" targetNamespace="http://pluri-biotech.com/20251208">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://pluri-biotech.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="plur-20251208_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="plur-20251208_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>plur-20251208_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>plur-20251208_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.3a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="plur-20251208.xsd#Cover" roleURI="http://pluri-biotech.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://pluri-biotech.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Dec. 08, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec.  08,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-31392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PLURI INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001158780<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0351734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">MATAM Advanced Technology Park<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Building No. 5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Haifa<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">3508409<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">972 74 710 7171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, par value $0.00001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PLUR<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0269001-8k_pluri.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://pluri-biotech.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0269001-8k_pluri.htm">ea0269001-8k_pluri.htm</File>
    <File>plur-20251208.xsd</File>
    <File>plur-20251208_lab.xml</File>
    <File>plur-20251208_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0269001-8k_pluri.htm": {
   "nsprefix": "PLUR",
   "nsuri": "http://pluri-biotech.com/20251208",
   "dts": {
    "inline": {
     "local": [
      "ea0269001-8k_pluri.htm"
     ]
    },
    "schema": {
     "local": [
      "plur-20251208.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "plur-20251208_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "plur-20251208_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 23
   },
   "report": {
    "R1": {
     "role": "http://pluri-biotech.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-12-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0269001-8k_pluri.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-12-08",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0269001-8k_pluri.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://pluri-biotech.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001213900-25-119651-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-119651-xbrl.zip
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ME0B.&*8NB<&%[@L!0%5S<E"Q#@O,07P7ED6W,JH.JC/88Z(6AK!ZGU*N#PH
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M7'ZS+_RN^,"G-Y_9GTZA]G7PU]$)+SJZHD:A;QLS_'?DC<V#_P=02P,$%
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MRI+*$^1.%*NL.PAJ*9Q;P"E-7E8<@\:A9-&+%\$^.F<): ,8QUD1Q6'P.BM
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M#+;=+"LJ.^<> -#Q)DQHU\1A..3"01J!E]IPXW@$\G@)E^4]-_Y..T6 76N
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M)U,B"BA*1O+-9J7BV)N<)H$&UR%\CSD8(\!$_;DIU"]8P_NH+F8$4&CO .N
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M;_5$H:F^RFW8:("FVKB15(8T0W=!%> ]"T4"YG%+)9%#&*>M.(+W[IEZHR'
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M#[:47?0ZP8"#O .]O*%:@?,)66/D9G[&RT]"]LQ..U'G/B&82'S=TH"Z$X2
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M6]?<+B:T>4_BO*;D)U>Y3MWLI$UDXJ^WOWM4[.I?7"Y>[.WL87 6D97(L>
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M-#D/X 87_PI>'1Z>!&>'/QZ=7QR>'1X$[TX.#COWG>Q?H%VX]^VS9V$ /YV
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M,4*)*%4K 6[)_S2A^E,+#J';NX]WD$2<Q4-EF#A^@JTWY6/#(2Q3)'8MA[E
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M@<>6B^L;+V^K9TACV/04G4@\".YSBNWB6E)9KW[/&7*:#B,&/;'3H.L29C6
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M&I7]U\;9><>HOS[:39RE>F)4G"IM;[RQT7G%:Q&NS"B&1X:%>FVW$S\5OY6
M.DM3&MA)Q)EA6;3M^9[BP(MM*K-W06,IFR">)/:2XKOA]M:"VV'V791JOX%J
M_X0._83:6ZX#0&BK5_MJ32*=ZI(]LFTEQSY,S5/G#0)L:<AJN$\>R7%WS3_-
M%'&)+N@$00ACRW&MU?2K@*J0YZFM$H?Z7Q$+'L2P7+((GIM[=1$(\CF)@;=E
M8F"5B8&5\<]\,*=VG%NF!F;JZ*7PZ[P$)LXEDUA&S-! _MZZ%%+>^O"E<3&'
MG%'NM;"8+":W52[ZJM&YOFQVNI]:5S7CK-VY:G<:P'DO3M/YTKTVQ"'MZT_-
MCM&\O&Y=_WFR2OJZY7#:*?OV"!+%G&4]Y93KY.2K!'+3K.;0[V4^@B4NX,H'
MT%S@5:HN19*6M[09-)P%$,V7+)2:3*Q)*N<R*I?"6@IKAJC 0!/!@$_ML4G4
M'Y:W U"FA$J+N%5R,@-#/0SO(K#:+,%:@<#/8I9>CJR76_Q/:TUQ:&FF%*V\
MR^L@G:V8':4?[)51>LGOEN!WJZ^%'G:3.-\B7J_MK6Z2[.W2&^\\E/#M13_?
M>21PD&"&VA$UWD;\;C2+ CGCG@V)Z4'HCVDXFU'<)("# [V[X(K(TE/D>!@Z
M>1H?+PG4X#1]&\C=Q.6@><-FJHI8YOYO?@!'0T5)HPV'*VGH7T /U@,V"Z#@
M2.#- 1V<\99@[#3:N&Z:$8[ >>93PL5N*GZXO+<%J-4J6+Z+GN*=X[K;6P"#
M9H031D&+.N3U5P0W'^-E$6<@\#0L)9[;?42KA]I -'C+,^]:S0] ^%094;]O
M\2[$6K"FV+-3$$99O'E0+[%=!\<LU>(5A)NA(;@QB(QX]K=.G]S4[!<$FIV&
MM$2DUJA&B:PS":HXUX8*HBR*0E\YU#8-Q#3$N^+RJ-@A+2=B:=(/[(7W!D[<
M=#4.&$86(/Q7G1R&M4%[V<]-/#>C0KA KO21%<)GRI6R'5H@0;FW6\?"X,3L
M0^O7#A0%L4]5MO?&_,/T;J)_N[^;[;3R7YD;@[*C2WZ7C3A+3<4D?21I9%RF
M,SD#!LM#^>]5F< '3!XJ'FN+^ATA4U!9WO/UMIRX4M6RC\0^.N 8$GI*V%!C
M8EF%)73!F!#!8M1_'W>Z2]DOJ.S7%Y3]533.=K,DCQ8"%?M8NXJV#< .B$)[
MQ5V9OG(3O#ND^@&R*H)PT>?[A>)PIXS1A\W(Z842UUML(4 -)8PY6GAL(E$+
M@1]Q VC.:E@7B2/+US%C8-- ?Y1N$S<2:ODQ;AWQ1*?>G>GW@_B"Q#+D[V@1
M\L=BIXU1K5*W@+:SZJT#V1MHJ;6;J+4'Q==:]!I'YC<;N2# 7\=$QY2V)&K+
M B7+DDN)'_.]JO8</HBV'=YQ0/[1W25?$_5(=^K?;6]5[JLQ_]^,ZT>>#_L.
M,0Q_)'XK;,FMZ;A,ZYGOSV:==7L+E,WH<A^>>";WN5NM]+?!D15_)I:G60/M
MMQJ83_P937S'\Q4MXO>)X[-'C5U'T(3G 2?T2-@(2X-</G,]M&[084 ->\0M
MR%\#^)[J-X1)76 J)<0"<P >MQX5?="-V5GTPJ[PXHI"F\A=)]/80U_H=9$[
M_N!W4MJ_3;5_ATNW?YF^_4+O,M/^8=OKV#,X&$7@$%H<.B%3.(IV]BP5SU1D
MTF(SIOB24%W$XS)WTF>J3U@ PI'0*J+O.6SP?4!')\\@9QD\K(^1,U&4(".F
M\DT\7S& 1B%PJ5";J%!'!7(H+GG[C^^.M!(9MV)C]V#@N [JQICS,5(M2%K%
M7SU[:+H#):;I !C4!'.\.(XR]>@3FIJ26@J35F.B&^ @  _$75=H#7Z'G]$:
M0K$?36AN/1AZOE!^3Y+J2L8@.<T<X5'"=^HXJ?^@Z>C5""L"[;R\C7/4K2DJ
MF0%,&M#VF]K"IT/?"V^(*6'V?FSP+ISA7"5=&EA&N8=NJ,H?%RCKE;V'6MXX
MD/N3$GNQDUHT#8,.K- ,(<O4Z>[:-\)+!;4';6!&.HO!74GQ^IY%ZF;?(BUT
M.H"O0?*:ATC(:1Z8%C-Y9^J>;[.S/C<S7NK)JO7D@2KQ.ELEYFK" RZ1+>G*
MR^(4%UTZ[17"$+0Y#DQ"P*EPV.-J^A 0W2^$R]&1030;!D@J,A&%:':PLP;6
M4)P"Y-V^-3G!FZ[0!$0/FI-%BI[;*GLNGGV*>/6M[K,Z1/;+#I&USG&4QC/?
MLKW9B)@\"&' SL&Q55C7_*E4$4OK!5Y]@AQ^0GY%>F35PQZ$'E41A/V<@O^N
M!2%1C2(6VJB/'0Q*@BEG.<=CACU3CKANW[%1 X!M31[FPUIXX\:W;9YM+1V/
M(NO.V\+[XJ [X(^'[A0FPW6/7*P)W _R,*9X9!_DKF\(F14Z@;#>!)H+OKSY
MO0:>NNG69(T,,TM"E;0I<)BB!9)G<4GAQQ-T ZI"8I8UZ8Z7DEYP2=_?*_HV
ML;T5[\ZR#>@\],(@0A&(T[MQMB:1.+6@7#00#E&?]@*3$UITD@&Y[M!_)Z3>
M$2$J5V+ O8;\+?3A66X(43XICQ=."2#-I-02^NCB7/ +3O2 AL ]^%E#WZ6.
M;(Z.+-J0M.:F#+#T0[./;4>!S-(8JK&3'9E)V',=R[T7YETX6M"@Y_E"4!_"
MVPJ?P\5ZMCW6.D_A%%S-<%UVQ.AJL0Y)$<F:?E]F>F2'980IDKG70>>$C2!%
MV#F))6PX-GUZAQ.AD6<9=:2D3DTA-J"4V$J#T:20PC(-?*FOFZ6OBS91K==]
M0^VA+8G8!;@@.0&%#,<LGJ;84O[-3?2\V8'26K:#""/!G1UWRW2=@D,Q-+']
M$>^"WKCO3/7$$4RD:1V*I0.W:<*^:._1^H2=LZD:B;CJEHVWAY.,WF$M'#>@
M'+F6;$7Z9[(#'/%Z_%I$*P-?W' ^5OM!C38HF=DUP<H#5$\T8H&&OPS;-TD7
M%NU#69\NJ&8R;/"0N284Q3LGX"S2(%VN"L<N^'2R$Z]1C7). SNK[\/ X8OY
MTR'06'=:-60[S*R>K>R+J!Z\4CV*KAY%ZBJ9$<?H\3YZ^Y;*"@>J\*O+\="\
MM7DBRH;X@MHG>8()=H4!3UU!')"<M+*BN$:JHT]-JYXO?DW3\=":HJX,594;
M#[-D_&UL$6('&3B(]LA]YZ%O$MVIWA0&7_5%4(-?4?U/BV)H'3G;'V$02P\R
M"&&,C ;_LH,<<@.Y*24QD,5!(NQZONG?$Q2?Y3MBE<#<@<9I,  >\D*H]TKA
MY112SH;!RQW4R[+DG+)D[#VDWT*^W,W](4' ?1 !VJ@G=MPW>0!PS[>"$J0M
MO2^>YN.TP<@W+Z.X@&VI&] QVV@-"P&W:6/V);++(J<\&X;3'Q-S:'SRW#XR
MV5Y<%0;GI81R*]&Q?GG_*GAE-%S[NW#SA*ORU88F9O%/4=Y$ ="(2FRWXDIO
MD25WN4!O)<[;QGL#)<[;XW'>'A_ZS IU#\I0=WT4:Q*-*X%=M7>TULQ-SGH@
MA+*&=C]T[>VM@]W]BE==$YI:_@)EAN_,G#A3\1OBVRW<,M>*1;=9RRJ<%F08
M5<#XVI'&(\^*YEY:2P?]$ONUOEMHUA;/-F-O!>/&_^K&+;;(8CS+Q+M]==K^
M\"=L=*\^77^^>/\?4$L#!!0    ( "" B5OQZD5B:$   +=- 0 :    96$P
M,C8Y,# Q,#%E>#0M,5]P;'5R:2YH=&WM?>MSVTB2YW=&\'^H]=U.4!>06G[V
MC-OK6$JBVYJ1)9U$M[?OXF(#)(L2QB#  4"I-7_]Y:M>>%"2QY)MV?-A6B9!
M5%565E8^?IGYZNWXW<'K?N_5V]%P#_ZK\'^OQOOC@]'K5S_Q?^';G^3K5SM'
M>[^KT_'O!Z/_>#3/L^JE>KR]K-0X6>A2'>I+=9(OXBSB#R)UJHMD_@A^"#\]
M-K^K]!_59IPF9]E+521GY]4O:A$79TFV6>7+EVK;_G.25U6^@$\>O7ZU\WKT
MQWDR22KU;.OQJY]V8';':]X[U5FEBQN\^$_9I%S^TGS931=GW@DO@T=A"'\6
M?U^553*_>O3Z<+0_?CLZ4>.W^Z?J=+3[_F1__+LZ/,)/1N:#_=&IVC\<'_5[
M'][N[[ZM/0Q_C_YK=+*[?SK<.1BIM\/?1FIG-#I4)Z-?]T_'HY/1GOH H]3?
M.#S<@Q_NOAT>_CI2NT?OWNV?GNX?':KFV/Z7;^!WO_=[I^/A> 23@D$.]H>'
MNR/U_AB^'A[B7-X=C_'9-R='[V02)T/ZY/WAWJCQ]N'N&%_[^"]/GT9J"/]^
M-X+']M0 G_M3.OO'*O\E?/Q/!7VX$?5[L CXT>[NT<G>_N&O![]'ZMT0Z3<&
M$L!;W]#J846G1P>TVM'Q6!V_/SE]/SP<J_$131B>VAWO ]6"N=(*82KC-;,^
ML>_J]_AEP]^&^P>T#R$=(GP8R#54\/[#4_@U?H/S/'V_\U<8'R83T1C!)$Y&
M__O]_@E-XQ2)U#()W$9\,=$ =P*X!'=[>'Q\L+]+4^'-\GYW,/QPNE5C(WQ/
MG>=.86WX MI;8;(1S\/_*9(<R'U\,-K[=42SV3TZ/!S1&LULU,[1X5"]V=\;
MP>,GO\J,WP-YY7N/6W=.COXV.MG<&PT/@/! N",Z(P='0& :%)\!:?,>SH*;
M[A9-_RUL-/Y(YHBLBYOY=G@R.NWW8+N X6$-'X8G)\@"\)K],1(2.8/X&$8:
M';T!IOKU9 0T&+\=CN$1F.7! >_7Z. @XET$[D*./=W_]3"2U>-LW_Y^C!/>
M1:+3).JC]GO"B<#M.!P0X_CDZ#>@S=[6'0D<%GN?3ZJ)X%Q63=&)G[4-#9(Z
MV(T&6=J%]SW,[,L2Y?@ &!@.S>[6-T^ 5M:3FYP^2K*9QE<^2[)'K_?+<J75
M7ESIE^J_W?\B]63[R?.'1X=4SZM'KS_$11%GE3H]CPM=OE2OWK]^\>1YM+V]
M_>JG]Z_59QN;_W_KR?,D:U4]:ANRO?4<M^0S$^#3)G$CP3VHSK71#H"&0E:D
MH=$.8%<+&"2!V5;G<16I>5ZHBS@%GBOT5"<7>A8A^7?/5]4_E_&Y>INGLR0[
M*]7!,;XG@L?.DA(80\]4/I\G4]WO/7WZ,UP%AZ=CO)R/AJ!;#/_V&UP-(/BS
M*BZ27 UVAYM'AQN1.GAQH)Y]>*%VAX?#O6&D8/2D*E5<ED""LKX '%P7P?R3
M4@%9DBK%B:Z6>:;P)S"?1=GOQ=E,E:O)W_6T4E5.WZ3)(JGB*LGA[?"P_D,7
MTZ34"A_%[Z=Y-DOXZW-85)+%<WB9*G6%I*G.(Q57\/"5JF!'\0TP8WZD<3KK
ML]_/X,5Q"A>;&12/=; :G 6_<PED*G#2SU]N;ZOEUF)+#9"??L^+CVHWJ7@"
M&_CT7U>95D^W:= 7D9JL*I7E%:ZFT#RUVD3&0!U8&*ZRWZO/(<)!@6CEM$@F
MFO@!9[5<%=/S&.8\+_*%.DY71:+VL^D6T /X_"*>Q4"Z8ID7]-KZB+OY8@E$
M"\=9+7$H.=C]7DF'70WBTM^S>(;'8 %[3/NQ@E-01*J5KT5<! 3-YPK&7L",
M^$O0?^"G=C% Y:G&AW(@(3\(:CL^J6@D& @8S+P?9IBF"HBB_[&*4\-1=C>/
M\65 CU+-]#S)X$ D,"RL PGR9##9^'QZRS<LN&"_#$T>XU9MH7C90X+QL://
M^KW=> GG-$W^"62DTZQ6)?R)K(C,G2-W7R+5#:WYM,H>G<<7FC9GH>.,Q)4]
MP+@I*.I(\L6\0\#,%8K 8\,7P[-":V2Z?J_&R?:;D)=G<(IF:@]$YF(";/-G
ME@!P&'5UJ34+)3D$5M2P--N"8P1<SD+'\!2OV"Q-IZ6^Q/7U>S1YQY)\$N9Y
MFN:7L$SY77/UL ?)E*9H7F#WX.7#8LJ;C/R8QG5;"M=6FH1BL-]#VI4DZ8]U
M4>:9W(^S!.[%*KVBFRJS_ZK.BWQU=DYR!+Y9Y"!!$M27%GJ6P)6'TX6KI2KR
MM*2?EN:?<'&IR95\QD)GRA)+'NCW+A-@VUCF00*F7$W/9;-)5I6\L\A9\*NR
M*E;P ;_L9)5J]6S[N15HVN?XX;2Z*VMJ'>V_^)[OK$HX6F4)5_!5Q[;/XBM0
M#Z9ZR??]FR*!3V "<;4JZ"_\]!2H:O[&'UR>)[ SL).QFFN@-UP3J3Z#_S_/
M4_P]GS^MWH.T@RTZ!54$5[5?%K%.29?@%_5[P #\LDF<?<2SG<"^)M6*=1-Y
M#?T>[R^K&B [Q*OJ/"](=,(;"[BMDH*Y+(TO\2.2GNHLO]!%AK(,YA=/C?R9
MIGFIOTNF0 4@ <TSSUI8HK%K_C'"@S?Z ^Z.[(SU"'[-=T1%.^*_;6ZJ-XE.
M9R_5<7RF?X'7_F.ELRG8KX_5YJ9XR5_M[?]FIN9;HH^?M)BB+_"S25[ >;*?
M[:3Q]*-ZO/4<9EGBV8(I?,)BK_5ZMUO&O-Y7/\$J6A8T ;W[X^9$@[X!JUX2
M%?R7OFAY*2[<7X*W"_ZF!D-ZI/X):<WD_1ZX+3RS5KM7(Q!U8+W"@V6'5"_=
MH06QZ:ME8GJBZ9/(G2T2^#)?I3-C9M)OSDEU8Q,+7P-VRI2D;& =!G.+0&9/
MTQ4:SQ%?Z3D8:LX<E3M$3T#)6!9ZK@N4V:7\EOQ#8!XO^=%+L4BL+$_HTB<S
MB91;O(&\F8!2<(&&_B0EM23''XKI&\-G<-O@OUE^X0>H*D?V[:1GR_++CO6+
MMR"JF5O?CP!T+&DO E"N.BX2[^KPGT:6?/R7I\](QXMA-V?HU3#V0K%*Y:HI
M]-DJ%2?&$NSQ57I&RGUE3>3ODO"L(+<>?-+5+Y(9VNUYX;LJX+3%197!3\^3
M)=A3!8Q$9U4>825JE06?Q&693Q/Y_=]S.%+J F:T*N  T)&&9\"DF(!=45VA
M/H\2!HX]/UI6.=Q=YE-/#U,#T@ 5R/)L2A()I!'.NTS8L86G;<.=>CJ35\@U
M>-)!2YQ]E_L>VC/7'SEWTI[^.&F?1/%Q$>-%UF4]D2ED#1BY9+UK&HV4"EZA
MR=L9*_.Z=W'Q47^?!FE(@@[E1306Y^]9T-.E\J[O\CK"I^BN)Z$&K\>_T,5;
MR?#B/T=W%MJ8H+F7R/PO\=-^[_#WTQ&[G/ O]>YO8_E77,[B?RCQV<D:@J]^
M3?/)VF].=8H>W^ !8].>DKPT%R4I*_C]T7A7[:S25%<PTYT\+F8B/Z_0/S(%
MZSXO2M+-?-+!B08A?/:],EE6@F:IAF>A!],PV:LW1X=C:\: A756Y"#E-J=Y
MFA<OD:TJ_>@U:MGHK85S"Z,:!3I2!P>[KW["-[SF#02!6Y!&:H;%>ZVJZ=V@
MS+)[:Q'#;9F=]7OQ;%:@:P:>N]E\GC]7N^CVU< =!5 N!E'^)LV!%YY$ZB29
MG>DY6DE@CQ8?(W7X5[7]\XL7VW:J*.<#IK$3AKFTS/BAL0[&7*_UU3]A7[TB
M_98#'O3)G<:![R9@<3O_=+SAKQF$S]PXWSE4X>(_PB4VN$0V6PDJ!)AS)?H6
MR 471)06<$].-/QGIE'G!(;.4\VN95)+:]'&@OZ+$IZ$( ?W<$P)+:H@LNA%
M$]D708]ZP3]^:H)69PJV6W%EP@_&)!Z0!@HW":N;'-\E+Z4HJ/-^+XALE&!"
MTZ)F&@.X\OHLK_!WN#[4P#!.P>-XL6,.AN!R\0M/!+A(B8J72PUVN;NF)GG^
MT3S4[\DL*.@'*L@J1?\M:'UTQ\73$O3R%$WA)2],;Z+$@1&K>'J.VO>&&>Z0
MYPO_LO04?RM0<0%DS>"]''&J\BWU >27? _32Q.4&_#;0;*!80&MU>#IAO(T
M)M8L!PE]KU6VHI 1_")X!LV# A1_I!9[>K,97G&GN@(SG*P%L'>2?$81T]:(
MXVP#YM#O<61LPP\3F2L>!G41<)@7<DD9)[/()SN'U(1'>'O.SF#K\ 5A\)-5
M"7A 8KGE4D\17(#S8DZ!+4R3*;D86J@,O'*9L&[(%\:LB"\SUA%#WRN,PS[S
MA/SC6_ V&./C9@Z'#K@[;7L[K:/?FVCK$H^ -<WZD'\7>@9_(O'.5C$>4-P\
M:VU55TMZH?L.O@+>!I;\)YVG#6.)M0Q.G.,-O07:5%[AU5?BSN*NP"^1D<Y,
M*%,."86!XN*J94\P$NJ]$W^Q/+\J@<!IBO<97K^-*'9XQON]%1B1J?]N$%Y6
MB,'-"./(N0CC["J^@/-#6VF-(6M!F4?Q71,,@!HV(Q:=@]8F\@[UU"D,%#%_
M!,N[T0*(YZ9Q-M4I&VJD3^ @P*YJ\+QV]&0IQ/UTHCNXI=]+2L/S3%E? T!5
M@@2N69:\V)LE4&B55ARXL>0L638M\X)F*I.I<M2:G1P(Z0Q*2 NA:W%N/9]K
MMFKAB.O"'/)\55GVZGJ_F5QM  HG@FD,^E;%@ ?8(::"=XBO>RDP.B$NC 07
M]C![QZL .9Q1*+[0T[R8@=PX=W*J,8( - (>E=<:F49WEJ4YSR <TD@S,@T(
M;"+1KX[C*SR%X=W!XPUEPH<(GR';@MR?R\H.SE=>8^U\2>+5J.'"!W$73S'
MB-Q;9R"X^J<?L_PRU:"_\H\1>B!A:/AIH>/2\E"_MRQR]A,Y5@0- GX3+\^C
MFNRW*DH;-]8VLH:ZZ=QPRZ3]'IY(.X0G&UB5.0/"9ZS0B/J3XE4/Z^([5%BN
MK-CW)A=O/.57Y?//C*)YW*$-WHWVV3W:30)H3WY11Q0!*%_BH'+3_Z)^0\ >
M?/V0XFL>&0P!?E%CN()?JF$13Y+I+^HP7F@F$MS^L/0G043,_ J_>=#1NB_
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MN?:K+@/?.6<=A@.?([HY[(A)3?-2KWQ,1NS5 0T*#B.<R'JV+6<\_,N&RU7
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M(9Y(\6 8Q[!?3R1!+%5+>8XF*ZQ[C8\DL;5WK4BP79[\4C0&.1)1@!61+$X
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M#LT/ZC<*@3%4I.FB<^3KQFYPWU1;O.-^N6]CM5O^!U!+ 0(4 Q0    ( ""
MB5O6.N!L,1L  %N'   6              "  0    !E83 R-CDP,#$M.&M?
M<&QU<FDN:'1M4$L! A0#%     @ ((")6W ./[ :D@  TET# !L
M     ( !91L  &5A,#(V.3 P,3 Q97@Q,"TQ7W!L=7)I+FAT;5!+ 0(4 Q0
M   ( "" B5OQZD5B:$   +=- 0 :              "  ;BM  !E83 R-CDP
M,#$P,65X-"TQ7W!L=7)I+FAT;5!+ 0(4 Q0    ( "" B5MV&9&J+@,  /$+
M   1              "  5CN  !P;'5R+3(P,C4Q,C X+GAS9%!+ 0(4 Q0
M   ( "" B5N89#;N_0H  '^&   5              "  ;7Q  !P;'5R+3(P
M,C4Q,C X7VQA8BYX;6Q02P$"% ,4    "  @@(E;17O7;%P'  #>5P  %0
M            @ 'E_   <&QU<BTR,#(U,3(P.%]P<F4N>&UL4$L%!@     &
-  8 F@$  '0$ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ea0269001-8k_pluri_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="plur-20251208.xsd" xlink:type="simple"/>
    <context id="AsOf2025-12-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001158780</identifier>
        </entity>
        <period>
            <startDate>2025-12-08</startDate>
            <endDate>2025-12-08</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-12-08" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-12-08" id="Fact000004">0001158780</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-12-08" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-12-08" id="Fact000010">2025-12-08</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-12-08" id="Fact000011">PLURI INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-12-08" id="Fact000012">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2025-12-08" id="Fact000013">001-31392</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-12-08" id="Fact000014">98-0351734</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-12-08" id="Fact000015">MATAM Advanced Technology Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="AsOf2025-12-08" id="Fact000016">Building No. 5</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-12-08" id="Fact000017">Haifa</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="AsOf2025-12-08" id="Fact000018">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-12-08" id="Fact000019">3508409</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-12-08" id="Fact000020">011</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-12-08" id="Fact000021">972 74 710 7171</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-12-08" id="Fact000022">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-12-08" id="Fact000023">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-12-08" id="Fact000024">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-12-08" id="Fact000025">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-12-08" id="Fact000026">Common Shares, par value $0.00001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-12-08" id="Fact000027">PLUR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-12-08" id="Fact000028">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-12-08" id="Fact000029">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
